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1. INTRODUCTION 
 
 
 
 
The process of wound healing in the liver, in contrast to other organs, leads often to a marked 
deterioration associated with portal hypertension and hepatocyte dysfunction. The 
development of hepatic fibrosis begins with infiltration of the space of Disse with increased 
amounts of collagens, glycoproteins and progresses up to nodule formation and cirrhosis 
(Davis et al., 1996). The liver damage is provoked by various chemical and biological agents, 
for instance by ethanol, oxidative stress, viruses and bacterial infections (Hoek et al., 2002). 
Liver transplantation, hyvopolemic shock or trauma also often entails the inflammation 
(Farzaneh-Far et al., 2001). 
The development of inflammation in the liver involves the close cooperation between 
parenchymal cells - hepatocytes and non-parenchymal (sinusoidal) cells (NPC).  
 
 
 
 1.1. Rat liver macrophages and their role in liver (patho)physiology 
 
 
1.1.1. Non-parenchymal cells 
 
Non-parenchymal liver cells (sinusoidal) cells represent a functional division between 
hepatocytes and the blood (Fig.1.1.).  
They include several types of cells (Table 1.1.): sinusoidal endothelial cells (EC) which 
compose the liver capillary wall; Kupffer cells (KC) which are the resident liver 
macrophages; hepatic Stellate (fat-storing, Ito) cells (HSC) which are located in the 
perisinusoidal space of Disse and are the main hepatic source of extracellular matrix 
components; Pit cells which are the kind of granular lymphocytes (Bouwens et al., 1992; 
Arias et al., 1982; Decker, 1987). 
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Fig.1.1. Liver sinusoid  
(Arias et al., 1982) Fig.1.1. 
 
 
 
 
Table 1.1. Types of non-parenchymal liver cells  Table 1.1. 
                (Decker, 1987; Blouin et al., 1977) Table 1.1. 
  Sinusoidal cell 
  Volume Number 
 
Kupffer cells 
(KC) 
44% 47,5% 
 
Hepatic Stellate 
cells  
(HSC) 
33% 37,5% 
 
Endothelial cells 
(EC) 
22% 12,5% 
 Pit cells 1% 2,5% 
 
 
 
A variety of functions has been reported for sinusoidal cells, like: filtration of particles (EC), 
endocytosis (EC, KC), phagocytosis (KC), secretion of bioactive lipids (eicosanoids) (EC, 
KC, HSC), secretion of cytokines (EC, KC, HSC), cytotoxic activity (KC), collagen 
production and synthesis of proteins of extracellular matrix (ECM) during inflammation 
(HSC); vitamin A storage (HSC), etc. (Bouwens et al., 1992; Decker, 1987). They also 
participate in liver growth, affecting hepatocyte’s proliferation (Malik et al., 2002). 
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1.1.2. Kupffer cells under normal physiological conditions and during inflammation 
 
Kupffer cells – resident liver macrophages – play a critical role in the maintenance of normal 
liver function and in the defence of the liver under inflammatory conditions (Bouwens et al., 
1992; Arias et al., 1982; Decker, 1987).  
Liver macrophages represent the largest population of tissue macrophages and constitute 
about 80-90% of macrophages of reticuloendothelial system (RES) (Biozzi et al., 1965). 
Within the liver they have a strategic anatomic position to control substances coming from the 
intestinal tract (Bouwens et al., 1992). Under physiologic conditions Kupffer cells are the 
long-living and self-renewing macrophage’s population, whose kinetics differ from other 
sinusoidal cells. Three immunocytohemically and functionally different populations of 
Kupffer cells have been found in normal rat liver. They are situated in the different area of 
liver lobulus (Table 1.2.). 
Kupffer cells can be distinguished from other sinusoidal cells by microscopy, histochemical 
analysis (endogenous peroxidase and tartrate-resistant acid phosphatase staining) and 
phagocytosis (Arias et al., 1982). 
 
 
Table 1.2. Zonal distribution and characteristics of Kupffer cells  
 
 Zone of lobulus 
 periportal midzonal perivenous 
 Zone 1 Zone 2 Zone 3 
Distribution of KC, % 1), 2) 431) / 442)  281) / 332)  291) / 222) 
Cell size  1), 3) “Large”  “Small” 
Characteristic 3) Mononuclear 
phagocyte 
 Small  
MC/MP/KC 
ED1/ED2 3) ED1+ ED2+  ED1+ ED2- 
Phagocytosis 1), 3), 4), 5) +++  ++ 1), 3), 4)/+++ 5) 
Lysosomal enzymes 1), 5) ++  + 
Galactosyl receptors 1), 5) +  ++ 
Cytotoxicity 1), 5) +  ++ 
LPS-induced IL-1 synthesis +  + 
Secretory response 4): 
  - resident cells 
 
++ 
  
+ 
  - LPS-Stimulated cells +  ++ 
Table 1.2. 
 
 
1) Bouwens et al., 1986; 2) Sleyster et al., 1982; 3) Armbrust et al., 1996; 4) Bykov et al., 2004; 
 5) Bouwens et al., 1992 
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Under inflammatory conditions Kupffer cells exert a large number of functions, including 
phagocytic activity, various immune reactions, the uptake and catabolism of lipids and 
enzymes, the secretion of bioactive factors, cytotoxicity, antigen processing, lipoprotein 
metabolism etc. (Bouwens et al., 1992; Decker, 1990; Arias et al., 1982). Moreover, there is 
evidence, that Kupffer cells possess a large capacity to kill tumor cells, resulting in a 
considerable defence of liver against metastasing cells (Decker, 1987). Additionally, during 
liver regeneration Kupffer cells play a stimulatory role by enhancing hepatocyte growth factor 
(HGF) expression (Takeishi et al., 1999). 
 
 
 
1.1.3. Liver fibrosis 
 
Hepatic fibrosis is a wound repairing process, defined by the accumulation of extracellular 
matrix proteins, especially collagen I and III, and by the synthesis of fibronectin, proteoglycan 
and laminin during injury as a response on chemical and biological stress (Kershenobich et 
al., 2003; Johnson, 1996). The major source of these compounds are the Stellate cells, which 
are thought therefore to be responsible for hepatic fibrogenesis and development of cirrhosis 
(Sokol, 2002). 
Liver injury often results in an activation of Kupffer cells, involving an increased 
phagocytosis and secretion of a large number of mediators, which, in turn, leads to an 
activation of T cells, hepatic Stellate and endothelial cells, magnification of the inflammatory 
response and stimulation of fibrogenesis (Sokol, 2002). 
The activated HSC undergo transformation into myofibroblasts with enhanced formation of 
ECM and synthesize a number of secretory products, including TGF-β, endothelin, matrix 
metalloproteases etc. (Albanis et al., 2001). Sinusoidal endothelial cells express intracellular 
adhesion molecule 1 leading to adhesion of neutrophils and magnification of inflammatory 
response. Furthermore, they enhance fibrosis through the modulation of plasmin-generating 
enzymes in response to transforming growth factor-beta 1 (Rieder et al., 1993). 
Defenestration and capillarization of the sinusoidal endothelium leads to a development of the 
fibrotic process (Braet et al., 2002). 
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1.2. Kupffer cell derived mediators 
 
Liver macrophages are the major producers of mediators during the inflammation (Table 1.3.)  
After their participation in the development of liver inflammation and fibrosis, these secretory 
products of Kupffer cells can be divided into two groups : (pro)-fibrogenic mediators such as 
IL-1β, TNFα, , IL-6, TxA2, PDGF, TGF-β (Kawada N., 1999; Malik et al., 2002; Tsukamoto, 
1999; Davis et al., 1996; Katagiri et al., 2004; Fisher et al., 1987) and  anti-fibrogenic agents 
like PGE2, IL-10, NO (Dieter, 1996; Davis, 1997; Kawada et al., 1992).  
 
 
Table 1.3. Basic biological active substances of liver macrophages Table 1.3. 
Lipids Peptides Inorganical substances 
Prostanoids: Cytokines:  
PGE2, PGD2, PGF2α, PGI2,  
TxA2  1), 2) 
IL-1, IL-6, IL-10,  
TNFα  1), 2) 
Reactive oxygen 
intermediates  1), 2) 
Leukotrienes: IL-12, IL-18   3) Nitric oxide  1), 2) 
5-HETE, LTA4 IL-8  4)  Carbon monoxide  8) 
   
 IFNα/β 1), 2)  
PAF  1), 2) TGF-β 5)  
 PDGF  
 ET-1  6)  
 MIPs, MCP, KC/GRO  7)  
 
 
1.2.1. Prostanoids 
 
Prostanoids are potent lipid eicosanoid mediators derived from arachidonic acid (Marks et al., 
1999). Within the liver, Kupffer cells are the major producers of prostanoids. They release 
prostaglandin E2, D2, F2α and thromboxane A2 (Table 1.4.). 
In opposite, hepatocytes appear to degrade prostanoids (Tran-Thi et al., 1987).  
 
1.2.1.1. Functions of prostanoids 
 
The functions of prostanoids are listed in the Table 1.5.  
 
 
1) Decker, 1990; 2) Dieter, 1996; 3)  Tsutsui et al., 1997; 4) Hisama et al., 1995; 5) Decker, 1991; 
6) Treffkorn et al., 2004; 7) Bautista, 2000; 8) Goda et al., 1998 
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Table 1.4. Distribution of prostanoid production among liver cells     (Dieter et al., 2001) 
Liver cells Prostanoid formation, % 
 Profile 
 
Total 
PGD2 PGE2 PGF2α TxA2 
HC - - - - - 
EC 35 12,25 6,30 5,25 11,20 
KC 60 45,00 4,80 1,20 9,00 
SC 4 1,48 0,88 0,16 1,48 
Other  liver cells 1 - - - - 
Table 1.4. 
Table 1.5. Functions of prostanoids  Table 1.5. 
General functions In the liver 
Prostanoids 
 Regulation tumor growth 1) 
 Modulation of different 
(patho)physiological processes 
(inflammation, immune regulation, 
arthritis, cancer etc.) 
 Up-reg. glycogenolysis in perfused liver after 
zymosan 2) 
 Up-/Down-reg. Ca2+ and K+ homeostasis 2) 
 Up-/Down-reg. contraction of HSC 2) 
 Regulate the size of fenestrae 3) 
PGE2 
 Modulation of immune response 4) 
 Pain response 1) 
 Fever generation 5) 
 Bone metabolism 5), 6) 
 Fertilization 5) 
 Causes vasodilatation 4) 
 Chemotaxis 4) 
 Down-reg. release of AA, formation of IP 
and DAG 9) 
 Tumorigenesis 6) 
 Alzheimer disease 6) 
 Regulates delivery of blood substances to 
parenchymal cells 6) 
 Up-reg. portal pressure 8) 
 Up-reg. glycose homeostasis 2), 7) 
 Down-reg. O2 uptake 8) 
 Down-reg. hepatic blood flow 8) 
 Down-reg. hepatic hemodynamics 8) 
 
In hepatocytes: 
 Up-reg. glycogenolysis 2) 
 Up-reg. hepatocyte’s DNA synthesis 10) 
 Down-reg. cAMP production 11) 
 Down-reg. the ammonium uptake and urea 
formation 8) 
 
 In Kupffer cells: 
 Mediates the release of inflammatory  
mediators12) 
 Up-reg. cAMP production 11) 
 Down-reg. release of AA, formation of IP and 
DAG 2) 
 Down-reg. LPS-induced release of TNFα, IL-1, 
IL-6 14) 
 Affects the LPS-induced release of NO 2), 15), 16) 
 Plays an autoregulatory function in KC 11) 
  
 In endothelial cells: 
 Regulates the size of fenestrae 3) 
 Regulates the exchange of material between the 
blood and liver parenchyma 17) 
Continued on next page 
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Table 1.5. (continued from page 6) 
General functions In the liver 
PGF2α 
 Up-reg. blood pressure 18) 
 Contraction of bronchial, vascular and 
arterial smooth muscle 19) 
 Down-reg. platelet aggregation 18) 
 Natriuresis 18) 
 Contraction of HSC, that may regulate the blood 
flow in the liver 20) 
 Down-reg. bile flow and bile acid secretion 21) 
 Regulates glucose metabolism 22) 
 Regulates blood flow and exchange of substances 
between the blood vessels and the hepatocytes 20) 
 Up-reg. hepatocyte’s DNA synthesis 10) 
 Mediator of intercellular communication between 
PC and NPCs 23) 
 
PGD2 
 Neuromodulator: promotes sleep 24) and 
hypothermia 27) 
 Inhibition of platelet aggregation 26), 27) 
 Relaxation of smooth muscle 
      contraction 26), 27) 
 Induction of bronchoconstriction 26), 27) 
 Attraction of inflammatory cells (T2 
cells, eosinophils and basophils) 26), 27) 
 
TxA2 
 Promotion of platelet activation 28) 
 Contraction of vascular smooth cells and 
glomerular mesangial cells  29) 
 Mediation in thrombotic, vasospatic and 
bronchospatic conditions  30) 
 Modulation of blood flow distribution 
and airway calibre  30) 
 Potent vasoconstrictor in the intrahepatic 
circulation system 31) 
 Up-reg. glycogenolysis in perfused liver  31) 
 Down-reg. bile flow and bile acid secretion  21) 
 Up-reg. portal resistance during liver injury  32) 
 Contraction of HSC (that may regulate blood 
flow) 20) 
 Participates in liver injury during endotoxemia  11)
 Is involved in pathogenesis of hepatic and 
endothelial dysfunction  33), 34) 
 
 
1) Bishop-Bailey et al., 2002 
2) Dieter et al., 1987 
3) Gatmaitan et al., 1996 
4) Tilley et al., 2001 
5) Funk, 2001 
6) Murakami et al., 2004 
7) Wisse et al., 1999 
8) Mitkov, 1990 
9) Lemieux et al., 2002 
10) Refsnes et al., 1994 
11) Decker, 1990 
12) Dieter et al., 1999 
13) Karck et al., 1988 
14) Goss et al., 1993 
15) Harbrecht et al., 1995 
16) Gaillard et al., 1991 
17) Dieter et al., 2001 
18) Liston et al., 1985 
19) Seibert et al., 1987 
20) Kawada et al., 1992 
21) Beckh et al., 1994 
22) Gomez-Foix et al., 1989 
23) Suzuki-Yamamoto et al., 1999b 
24) Matsumura et al., 1991 
25) Ueno et al., 1982 
26) Hirai et al., 2001 
27) Kanaoka et al., 2003 
28) Hamberg et al., 1975 
29) Mene et al., 1986 
30) Ogletree, 1987 
31) Fisher et al., 1987 
32) Yokoyama et al., 2003 
33) Katagiri et al., 2004 
34) Graupera et al., 2003 
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1.2.1.2.  Arachidonic acid cascade 
 
The biosynthesis of prostanoids is composed of three successive steps, the so-called 
“Arachidonic acid cascade” (Fig. 1.2.): the release of AA from phospholipids by 
phospholipase (Ambs et al., 1995; Marks et al., 1999) followed by conversion of free AA into 
PGG2/H2 by PGH2/G2-synthases (or cyclooxygenases (COX), and the subsequent conversion 
of PGH2 into different prostaglandins or thromboxane via specific final synthases (Smith et 
al., 2000). 
 
In liver macrophages there are two different mechanisms for the activation of AA cascade. 
The immediate pathway of the AA cascade is activated rapidly (within minutes) after stimuli 
like AA, zymosan, C3a, phorbol esters or calcium ionophores and is the result of activation of 
pre-existing enzymes such as cPLA2, COX-1 and TxA2 synthases. The delayed pathway 
shows a lag phase of several hours and is activated by e.g. LPS- and cytokine which results in 
the expression new enzymes such as COX-2 (Dieter et al., 2000). 
 
 
Fig.1.2. Schematic presentation of arachidonic acid cascade  
(Flower et al., 2003)
Fig. 1.2.  Flower, 2003 
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1.2.1.3. Role of cPLA2 
 
The level of prostanoid synthesis is mainly defined by the availability of free AA. Under 
physiological conditions the intracellular level of AA is very low; it is etherified with sn-
glycerol-2 position of phospholipids. The release of AA from phospholipids can occur 
through the action of a number of different phospholipases (PL A2, C, D), phosphatidic acid 
phosphohydrolase and diacylglycerol lipase (Marks et al., 1999; Diaz et al., 2003; Dennis, 
2000).  
The (re)-incorporation of free AA (including from dietary fatty acid) into membrane 
phospholipids is performed through both, arachidonyl coenzyme A synthetase and 
lysophosphatide acyltransferase. Therefore, free AA level inside cells is dependent on the rate 
of its incorporation into membrane lipids versus its liberation from this pool (Fig. 1.3.) 
(Marks et al., 1999). 
 
 
 
Fig.1.3. Regulation of free arachidonic acid pool
(Marks et al., 1999)
Fig. 1.3. 
 
 
The release of AA can be carried out: 
1) directly, by PLA2: Among a number of phospholipases A2 groups (Marks et al., 1999; 
Diaz et al., 2003), only Group IV cytosolic phospholipase A2 is thought to participate in the 
free AA generation in rat liver macrophages. Besides mRNA and proteins of Group IV cPLA2 
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(Ambs et al., 1995; Dieter et al., 2002), only mRNA encoding Groups V and IIa secretory 
PLA2 are constitutively expressed in liver macrophages. Cytosolic PLA2 is defined in many 
cells and tissues (macrophages, platelets, neutrophils, eosinophils, endothelial cells, smooth 
muscle cells, alveolar epithelial cells, renal mesangial cells, keratinocytes, fibroblasts, U937, 
THP-1, osteoblasts, kidney, spleen, brain, lung, heart, testis) (Marks et al., 1999). The protein 
possess 749-amino acids and has a calculated molecular weight of 85 kDa but shows a 110 
kDa weight on SDS-PAGE (Ambs et al., 1995). The activity of the enzyme depends on Ca2+ 
and phosphorylation (Ambs et al., 1995; Dieter et al., 1988). 
However, for the activation of AA cascade, Ca2+ seems to be more important than  
phosphorylation (Ambs et al., 1995). Ca2+ binds to the C2 domain of cPLA2 and induces its 
translocation from cytosol to membranes, regulating cPLA2-membrane association (Leslie, 
2004). 
The treatment of cells with PMA, zymosan or A23187 (Ca2+-ionophor) induces a rapid 
upregulation of cellular free AA followed by an immediate prostanoid release (Table 1.6.) 
(Ambs et al., 1995; Duyster et al., 1992). In contrast, LPS induces an upregulation of free AA 
after 4h (delayed release). Recent findings (Dieter et al., 2002) show that LPS induces an 
upregulation of cPLA2-protein. 
 
 
Table 1.6. Activation of cPLA2  
                  (Ambs et al., 1995; Dieter et al., 2004)  Table 1.6. 
 
 
Effect Agent 
Phosphorylation of cPLA2 Free Ca2+ AA release 
PMA Up-reg. , through  PKC-β and MAPK --- Up-reg.  release of AA  (within minutes) 
Zymosan Up-reg. , through  PKC-β and MAPK Up-reg.  - `` - 
A23187 --- Up-reg.  - `` - 
LPS Up-reg. , through MAPK Up-reg.  Up-reg.  release of AA (>4h) 
 
 
 
2) by the combined action of phospholipase and DAG lipase: free arachidonic acid can 
also be generated by combined action of PLC or PLD with DAG lipase (Fig. 1.3.) (Duyster et 
al., 1992; Dieter et al., 1993).  
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1.2.1.4. Role of cyclooxygenases in prostanoid formation 
 
Prostaglandin endoperoxide H synthase (or cyclooxygenase) catalyses the first two steps in 
the biosynthesis of prostanoids from free AA: i) Oxidation of AA to hydroperoxy 
endoperoxide PGG2 (cyclooxygenase activity of enzyme) and ii) its reduction to the hydroxy 
endoperoxide PGH2 (peroxidase activity) (Smith et al., 2000; Vane et al., 1998). Since 1990 
two isoforms of COX are known – COX-1 and –2 (Table 1.7.). COX-1 is a constitutively 
expressed enzyme and defined in most tissues. COX-2 is an inducible enzyme and appears 
after the stimulation of cells by various agents, e.g. LPS, cytokines, PDGF etc. (Smith et al., 
2000).  
Recent evidence demonstrates the existence of a splice variant of COX-1 (Chandrasekharan et 
al., 2002), the so-called “COX-3”, in canines. The expression of  “COX-3“ mRNA in rat 
central nervous system has been recently discovered (Kis et al., 2004). Moreover, the 
existence of other COX’s isoenzymes is assumed (Davies et al., 2004). 
 
Table 1.7. Characteristics of COX isoenzymes  
                 (Marks et al., 1999; Smith et al., 2000)  Table 1.7. 
 
 COX-1 COX-2 
N of Amino acids 576 587 
Calculated MW, kDa 66 67 
Relative mobility on SDS-PAGE, 
kDa 
72 72-74 
Synthesis Constitutive Inducible 
Main physiological functions  Regulation in stomach and 
intestine function 
Inflammation and 
injury 
Coupling to PLA2 Depends on the cell type and the stimulus 
(Marks et al., 1999, p. 77) 
 
 
1.2.1.5. Conversion of PGH2/PGG2 into prostanoids 
 
The enzymatic conversion of PGH2 into prostanoids is performed by final prostanoid 
synthases (Fig. 1.2.). Till now several (iso)enzymes have been isolated, characterized and 
cloned (Ogorochi et al., 1987; Tanaka et al., 1987; Meyer et al., 1996; Jakobsson et al., 
1999b; Murakami et al., 2000; Tanioka et al., 2000; Tanikawa et al., 2002; Lazarus et al., 
2002a). Since Kupffer cells synthesize PGE2, PGD2, PGF2α and TxA2, the enzymes for their 
production will be discussed below. 
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1.2.1.5a. PGE2-synthase 
 
The isomerization of PGH2 into PGE2 is catalysed by PGE2-synthase (PGES, EC 5.3.99.3, 
systematic name (5Z,13E)-(15S)-9α,11α-epidioxy-15-hydroxyprosta-5,13-dienoate E-
isomerase). PGES is synthesized almost in all tissues and cells, and the existence of various 
types of PGE2-synthases has been proposed earlier (Ogorochi et al., 1987; Tanaka et al., 
1987).  
At present, three distinct types of PGES are identified, cloned and investigated, i.e. GSH-
specific and non-specific membrane-associated synthases (mPGES-1,-2) and cytosolic type 
(cPGES), their properties are briefly shown in Table 1.8. 
 
 
Table 1.8. Characteristics of PGE2-synthases  Table 1.8. 
 
 mPGES-1 1) 
 
mPGES-2 2)  cPGES 3) 
N of Amino acids 152-153 377-384 160 4) 
Calculated MW, kDa 16-18 33 23 
Relative mobility on SDS-PAGE, 
kDa 16 33 23-25 
GSH-dependent activity + --- + 
 
 
 
The first microsomal types of PGH-PGE isomerases have been partially purified from 
microsomal fractions of bovine (Jakobsson et al., 1999a) and sheep (Moonen et al., 1982) 
vesicular glands; the enzymes activity is  dependent on glutathione (Table 1.9.). 
Later, PGES has been purified and identified as a member of MAPEG protein superfamily. 
This group of enzymes consists of membrane associated proteins, which are involved in 
eicosanoid and glutathione metabolism. The glutathione-dependent membrane-bound 
prostaglandin E2 synthase was previously designated as PIG12 or MGST1-L1 and is now 
known as mPGES-1 (Jakobsson et al., 1999a; Jakobsson et al., 2000; Murakami et al., 2000). 
 
 
1) Lazarus et al., 2002; Jakobsson et al., 1999;  
2) Tanikawa et al., 2002; Hu et al., 2002; Watanabe et al., 1999; 
3) Tanioka et al., 2000 
4) Zhang et al., 2003 
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Table 1.9. PGE2-synthases: the history of investigation 
 
PGH2 activity  Cells, tissue Fractions 
Km, 
μM 
Vmax, 
nmol/ 
min/mg 
min GSH 
for max 
activity, mM
GSH: 
Kmax, 
μM 
 
pH optim Rel. mob. 
on SDS-
PAGE, 
kDa 
Sheep 
vesicular 
glands1) 
Microsomal  30 0.5  5.5-7.0 60, 67 
IgG1 (hei-7) 40  2  6,5-7,5 17,5 Sheep 
vesicular 
glands2) IgG2 (hei-26) 150  <0,5  6.2 180 
Deferent duct 
etc.: GSH-
dependent 
25.7 ≤ 112 0.2  6-7  
Rat tissues3) Heart, spleen, 
uterus : GSH-
independent 
82.6 ≤1,1 ---  6-8 (9-12)  
Microsomal 
fractions 
Bovine hearts4) Microsom. fr. 24  - - >6.0 31 
peak 1 147 380 5 61 5.4 24.5, 25Numan brain 
cytosol5) 
 
peak 2 308 720  86 5.4 25 
Ascaridia galli6)    0.51 75  
24.3-
25.7 
(7 
subunits)
Human brain 7) Cytosolic fr.  1.21    27.5 
GST M2-2 141 282 121 26.5 
Cytosolic 
fractions 
Rec. (E. coli) 7) 
GST M3-3 1500 923 
2,5 
76 
8.0 
27.5 
 
 
 
 
The cDNAs for human, mouse and rat mPGES-1 have been further cloned and their 
properties were investigated (Lazarus et al., 2002a; Yamagata et al., 2001; Jakobsson et al., 
1999a) (Table 1.10.). mRNA has been found at high levels in A549, HeLA cell lines, at 
intermediate levels in placenta, prostate, testis, mammary gland and bladder (Jakobsson et al., 
1999a). 
 
1) Moonen et al., 1982 
2) Tanaka et al., 1987 
3) Watanabe et al., 1997 
4) Watanabe et al., 1999 
5) Ogorochi et al., 1987 
6) Meyer et al., 1996 
7) Beuckmann et al., 2000 
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Table 1.10. Cloning of PGES Table 1.10. 
 
PGH2 activity  Ref Protein, host, 
nomenclature 
Bacterial system 
Km, 
μM 
Vmax, 
nmol/ 
min/mg 
GSH: 
Kmax, 
μM 
 
Rel.mob. 
on SDS-
PAGE, 
kDa 
1) Rec., human, 
NP_004869, O14684  E. coli   250 + 15-16 
2) Rat/mouse/human, 
NP_071860, 
NP_067594, 
Q9JM51, BA96084 
HEK293 
cells  
Rat/ 
Mouse/
Human 
 ≈260-370* +  
3) 
Rec., rat, NP_067594, 
AAG24803 
Chinese hamster 
ovary cells (CHO-
K1)  
 1000 + 17 
4) Rec., rat, NP_067594, 
BAB20597 Rat testis    +  
5) Bovine,NP_776868, 
AAK51127 Ovarian follicias    + 17 
6) Rec., mouse, 
BAB71813, 
NP_071860, Q9JM51
E. coli  130 1816 37 17 
7) Rec., human, 
NP_004869, O14684 E. coli  160 
170*
103 710 18 
mPGES-1 
 
8) Rec., human, O14684 Bacilovirus-Sf9  14 400 750 17 
mPGES-2 9) Rec., monkey, 
NP_079348, 
BAB01608 
E. coli (BL21)  28 3300 --- 33 
cPGES 10) Rec., human/Rat brain 
cytosol E.coli  14 190 + 26 
* ng/30 sec/10µg  
 
 
 
Another PGES was purified from cytosol fractions of human brain (Ogorochi et al., 1987) and 
Ascaridia galli (Meyer et al., 1996) (so-called p23). Recently, the cDNA for cPGES/p23 has 
been identified and cloned; the protein, expressed in E.coli, exhibits GSH-requiring PGE 
synthase activity (Tanioka et al., 2000). 
Finally, the novel-type PGES has been purified from microsomal fraction of bovine heart 
(Watanabe et al., 1999).  
 
1) Jakobsson et al., 1999b 
2) Murakami et al., 2000 
3) Mancini et al., 2001 
4) Yamagata et al., 2001 
5) Filion et al., 2001 
6) Lazarus et al., 2002a 
7) Thoren et al., 2003 
8) Ouellet et al., 2002 
9) Tanikawa et al., 2002 
10) Tanioka et al., 2000 
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This enzyme, called mPGES-2 has been identified and cloned; the examination of enzymatic 
properties of mPGES-2 shows GSH-independency (Tanikawa et al., 2002). It requires SH 
reagent (especially DTT), and has the highest kcat/Km and Vmax for PGH2 among other PGES 
types (Tanikawa et al., 2002). The amino acid sequence of mPGES-2 does not exhibit 
homology with the mPGES-1, assuming that mPGES-2 does not belong to the MAPEG 
protein family (Jakobsson et al., 1999a; Tanikawa et al., 2002; Jakobsson et al., 2000). The 
mPGES-2 mRNA is detected in many cells and tissues (genital organ, brain, lymph nodes, 
heart, skeletal muscle, kidney and trachea) (Tanikawa et al., 2002).  
 
 
 
 
1.2.1.5b. PGD2-synthase 
 
 
Prostaglandin D2 is synthesized by PGD2-synthase (Christ-Hazelhof et al., 1982) (PGDS, EC 
5.3.99.2, (5,13)-(15S)-9α,11α-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase). The 
function of PGDS in the liver is not get clear; the short characteristic for PGDS is provided 
above (Table 1.5.) (the more detailed information see reviews: Marks et al., 1999; Urade et 
al., 2002; Kanaoka et al., 2003). 
 
Two isoforms of enzyme have been purified and further investigated: 
1) Lipocain PGDS (“brain type”): GSH-independent secretory enzyme from lipocain 
superfamily. It has been isolated firstly from rat brain (Shimizu et al., 1979); it is 
expressed in the brain and testis and secreted into cerebrospinal fluid and the seminal 
plasma as β-trace (Tanaka et al., 1997). 
2) Hematopoietic PGDS (“spleen type”): it is GSH-dependent, cytosolic enzyme, has 
been isolated firstly from rat spleen (Christ-Hazelhof et al., 1982) and is expressed by 
mast cells, histiocytes and dendritic cells of the spleen, thymus, skin and KC in the 
liver (Kanaoka et al., 2003). 
Both isoenzymes convert PGH2 into PGD2, consist of 183-199 amino acid and have the 
molecular weight 21-27 kDa (Urade et al., 1989; White et al., 1992; Hoffmann et al., 1993). 
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1.2.1.5c. PGF2α-synthase 
 
Prostaglandin F2α is secreted in vivo in form of 9α-,11α-PGF2, i.e. PGF2α (which is also 
synthesized by Kupffer cells) and  9α,11β-PGF2, i.e. 11-epi PGF2α (Marks et al., 1999). Three 
pathways exist for prostaglandin F2α synthesis (Watanabe, 2002; Helliwell et al., 2004): 
1) from PGH2 to PGF2α: PGH2 9,11-endoperoxide reductase-activity of PGF2α-
synthase (PGFS); 
2) from PGE2 to PGF2α: PGE2 9-ketoreductase-activity of PGFS; 
3) from PGD2 to 11-epi PGF2α: PGD2 11-ketoreductase-activity of PGFS. 
PGF2α-synthases are all NAPDH-dependent and have 323 amino acids / MW about 36-37. 
They are classified by both origins and enzymatic properties: 
1) PGF2α-synthase (EC 1.1.1.188): this enzyme shows 11-ketoreductase-activity and 
9,11-endoperoxide reductase-activity. 
 
Two isoenzymes exist: 
• Lung-type PGFS I: was isolated firstly from bovine lung (Watanabe et al., 1985); 
Km(PGH2)=10 µM; Km(PGD2)=120 µM; 
• Liver-type PGFS II: was isolated firstly from bovine liver (Chen et al., 1992); 
Km(PGH2)=25 µM; Km(PGD2)=10 µM; 
The difference between the isoforms are: different sensitivity of PGF2α, to metals, 
chloride ions, salts (CuSO4, HgCl2) and immunoprecipitation (Chen et al., 1992). Both 
isoenzymes were characterized, cloned and expressed in E. coli (Watanabe et al., 1991; 
Suzuki et al., 1999; Suzuki-Yamamoto et al., 1999a). 
2) Aldehyde reductase (EC 1.1.12) was isolated firstly from human liver (Hayashi et 
al., 1989). It shows only PGH2 9,11-endoperoxide reductase-activity, Km(PGH2)=100 µM; 
PGD2-activity was not detected. 
 
1.2.1.5d. TxA2-synthase 
 
Thromboxane A2 is synthesized by TxA2-synthase (TxAS, EC 5.3.99.5, (5Z,13E)-(15S)-
9a,11a-epidioxy-15-hydroxyprosta-5,13-dienoate isomerase). It has been firstly identified in 
the microsomal fraction of platelets (Needleman et al., 1976), thereafter in rat seminal 
vesicles (Moncada et al., 1976) (Table 1.11.). 
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Table 1.11. TxA2 synthase: history of their investigation  Table 1.11. 
 
PGH2 activityCells, tissue Ref. 
Km, 
μM 
Vmax, 
nmol/ 
min/mg
pH 
optim 
Ratio 
TxA2:HHT 
Relative mobility on 
SDS-PAGE, kDa 
Human/horse platelets 1)      
Rat seminal vesicles 2)      
Human platelets 3)      
Human platelets 4)  84* 6.5-9.0   
Human platelets 5)  57  1:1 58,8 
Porcine lung 6) 12  7.5 1:1,6-2.0 53 
Human platelets 7) 24     
Human paltelets 8) 10   1:1 58 
*nmol/20sec/mg 
 
 
 
Thromboxane synthase consists of 533-534 amino acids and has a molecular weight of 58-60 
kDa (relative mobility 56-60) dependent on the host organism (Wang et al., 2002; Shen et al., 
1998). 
TxA2 synthase is a membrane cytochrome P450-like protein: UV-VIS, MCD and EPR indicate 
(Hsu et al., 1999) that TxAS has a typically low spin cytochrome P450 heme with an oxygen-
based distal ligand (Haurand et al., 1985). 
TxAS catalyzes two reactions with the same substrate - PGH2: 1) the conversion of PGH2 into 
TxA2 and 2) the cleavage of PGH2 to form 12-HHT and malondialdehyde (Hecker et al., 
1989). Enzymes, purified from platelets, and recombinant kidney TxAS produced equal 
amounts of TxA2 and 12-HHT (Hsu et al., 1999). Enzymes, purified from porcine lung, and 
for recombinant protein from baculovirus system, the ratio of synthesized TxA2:12-HHT was 
approximately 1:2 (Yokoyama et al., 1993). During catalysis, TxAS undergoes a “suicide” 
inactivation, which occurs at the reactive site of the enzyme (Jones et al., 1990). 
 
 
1) Needleman et al., 1976; 
2) Moncada et al., 1976; 
3) Sun, 1977; 
4) Hammarstrom et al., 1977; 
5) Haurand et al., 1985; 
6) Shen et al., 1986; 
7) Jones et al., 1990; 
    8)   Nusing et al., 1990. 
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DNA of TxAS has been cloned (Table 1.12.), and the recombinant protein (E. coli) showed a 
high specific activity, as purified enzyme (Hsu et al., 1999; Yokoyama et al., 1993). 
The existence of two isoforms of TxAS in human lung has been supposed after screening of 
human lung cDNA library (Ohashi et al., 1992), but last publications reported about only one 
known isoforms (Wang et al., 2002). 
 
Table 1.12. Cloning of TxAS  Table 1.12. 
 
PGH2 activity Protein, host, 
nomenclature 
Tissue, 
cells/Bacteria
l system 
Ref.
Km, μM Vmax, 
nmol/ 
min/mg
Ratio 
TxA2:HHT
:MDA 
 
Relative 
mobility on 
SDS-PAGE, 
kDa 
Human platelet, 
NP_112246, 
NP_001052; 
BAA07011, S48161, 
A41766 
Spodoptera 
frugiperda Sf9
1) 
 130 1.0:1.8 58 
Human lung, 
NP_001052, P24557, 
A41766, AAA60618 
 
TxAS I   534aa/60,6*
Human lung, 
NP_112246, B41766, 
AAA60617 
 2) 
TxAS II   460aa/52,4*
Mouse, lung, 
NP_035669, 
AAB39850, P36423, 
JN0683 
 
3)     
Rat, bone-marrow cells, 
NP_036819, P49430, 
BA05962, S42404 
Peritoneal 
macrophages 
4) 
    
Porcine lung, 
NP_999211, P47787, 
AA31127 
Spodoptera 
frugiperda Sf9
5) 
   60,5* 
Rat kidney, NP_036819, 
P49430, BAA22574 
 6)     
Recomb., human E. coli 7) 20 12000 0.94:1.0:0.93 56 
* calculated MW 
Table 1.12. 
1) Yokoyama et al., 1991; Yokoyama et al., 1993 
2) Ohashi et al., 1992 
3) Zhang et al., 1993 
4) Tone et al., 1994 
5) Shen et al., 1994 
6) Tsutsumi et al., 1997 
7) Hsu et al., 1999 
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1.2.2. Nitric oxide 
 
1.2.2.1. Nitric oxide and its main functions in the liver 
 
Nitric oxide is the product of the nitric oxide synthase (NOS). It exists as a number of  
inorganic free radicals such as ٠NO, NO-, NO+, NO2, NO2-, NO3-, N2O3, S-nitrothiols, 
peroxynitrile or nytrosil-metal complexes (Bogdan, 2001). The enzymatic reaction includes 
the oxidation of the one guanidine nitrogens of substrate L-arginine by molecular oxygen to 
form NO and L-citrulline (Muriel, 2000) (Fig. 1.4.). 
 
 
 
Fig.1.4. Nitric oxide synthesis from L-arginine
(Muriel et al., 2000)
 
Fig. 1.4. 
 
Nitric oxide has been identified at first as an endothelial derived relaxation factor (EDRF) 
(Ignarro, 1990) and antiplatelet substance. It is produced in neuronal cells (Bredt et al., 1990), 
leukocytes (McCall et al., 1989), macrophages and endothelial cells (Curran et al., 1989) and 
other cells (Amber et al., 1988; Moncada et al., 1991). 
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The role of NO in the liver is not yet clear. Enhanced production of NO during cirrhosis might 
lead to the development of the hyperdynamic circulation, whereas the local deficiency of NO 
in the liver might lead to portal hypertension (Table 1.13.). 
 
 
Table 1.13. Functions of NO in the injured liver 
 
• exerts a hepatoprotective effect during endotoxemia (Harbrecht et al., 1995; Nishida et al., 
1994; Wang et al., 1995) 
• Down-reg.  the platelet aggregation (Mellion et al., 1981) 
• Down-reg.  the contraction of SC and affects the hepatic microcirculation (Farzaneh-Far et 
al., 2001) 
• establishes of the hyperdynamuic circulation (Farzaneh-Far et al., 2001) 
• plays both cytotoxic and cytoprotective role during liver injury and carcinogenesis 
(Farzaneh-Far et al., 2001; Vos et al., 1997; Lirk et al., 2002)  
• promotes injury though its oxidant properties (Gardner et al., 1998) 
• inhibited of the mitochondrial respiratory chain  enzymes and gluconeogenesis (Horton et 
al., 1994) 
• inhibits total protein synthesis in hepatocytes (Curran et al., 1990)  
• prevent necrotic cell death following endotoxemia-induced liver injury (Ou et al., 1997) 
• preventes hepatocytes apoptosis in vitro and in vivo (Jones et al., 1998; Li et al., 1999) 
 
 
1.2.2.2. Synthesis of nitric oxide 
 
NO synthases (NOS) catalyse the oxidation of L-arginine to nitric oxide and citrulline. Three 
subtypes have been identified: 
- neuronal NOS (type 1, nNOS) is a constitutive isoform, Ca2+/calmodium dependent, main 
function in neurotransmission; 
- inducible NOS (type II, iNOS) is not expressed under normal conditions, but can be 
induced by cytokines and LPS in many cell types (Nussler et al., 1993; Vos et al., 1997), in 
response to liver injury from diverse insults, including hepatotoxins, endotoxemia, and 
ishemia-reperfusion (Nussler et al., 1993; Kroncke et al., 1997);  the localization of iNOS is 
usually assumed to be cytoplasm, but the study of endotoxemia (Vos et al., 1997; Nussler et 
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al., 1993) showed hepatocyte’s iNOS more intensely in the plasma membrane than in the 
cytoplasm. 
 
- endothelial (type III, eNOS) - constitutive isoform, Ca2+/calmodium dependent, importent 
role in vasorelaxation.  
NOS are primarily cytosolic, although eNOS can be mirystilated and localized in  membranes 
(Appleton et al., 1996). Both constitutive synthases rapidly synthesize small amounts of NO 
in response to increases in intracellular calcium and supposed to regulate physiological NO 
homeostasis and cellular signalling (Leifeld et al., 2002). The inducible NO synthase is under 
transcriptional control and produces high amount of NO induced by cytokines or endotoxin. 
The increased NO production in the liver results from enchanced expression of iNOS in 
hepatocytes and KC: LPS is a weak inducer of hepatocyte’s iNOS; iNOS in the LPS-treated 
liver, highly expressed in inflammatory cells and Kupffer cells (Vos et al., 1997; Pollock et 
al., 1995; Moncada et al., 1991). 
 
 
1.2.2.3. Regulation of NOS 
 
The NOS activity is also dependent on a number cofactors, including FAD, FMN; H4B and 
glutathione (Moncada et al., 1991; Muriel, 2000). Several NO synthases inhibitors are used in 
the studies of NO signalling: salycilates (Vos et al., 1997); NG-nitro-L-arginine methyl ester 
(L-NAME) and NG-monometyl-L-arginine (L-NMMA), which inhibit more specifically 
eNOS than iNOS (Vos et al., 1997); S-metylisothiourea (SMT) and L-NIL (L-N6-(1-
Iminoethyl) lysine, which are preferential iNOS inhibitors (Vos et al., 1997).  
 
 
1.2.3. Synthesis of cytokines by rat liver macrophages 
 
Cytokines constitute a major class of mediators responsible for activation of liver cells in vitro 
and in vivo. They can be divided into pro-fibrogenic (interleukin-1, tumor necrosis factor-
alpha) and anti-fibrogenic (interleukin-6, interleukin-10) and mitogenic (transforming growth 
factor-alpha, platelet-derived growth factor, insulin-like growth factor), mediators 
(Tsukamoto, 1999; Decker, 1990). Elevated amounts of TNFα and IL-1β has been found in 
culture medium of LPS-stimulated rat liver slices (Olinga et al., 2001). 
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1.2.4. Influence of mediators on the development of liver fibrosis 
 
One initial step of the hepatic inflammation is the activation of resident liver macrophages 
and the subsequent secretion of a large number of inflammatory mediators. The secreted 
mediators induce a new wave of cell interactions and responses, leading i) to activation, 
proliferation of liver Stellate cells and their transformation into myofibroblasts; ii) to the 
activation of hepatocytes and liver endothelial cells resulting in impaired blood flow and 
further ischemic injury; iii) to deposition of excessive extracellular matrix resulting in hepatic 
fibrosis (Sokol, 2002; Kershenobich et al., 2003; Bissell, 1998). The prolonged hepatocellular 
damage may progress to cirrhosis in which the replacement of the normal hepatic constitution 
is replaced by fibrous septa and nodules of regenerative parenchyma (Johnson, 1996). 
Taking all data together, the following scheme (Fig. 1.5.) summarizes the influence of two 
groups of Kupffer cell-derived products on other liver cells during the liver inflammation, 
accelerating (pro-fibrogenic mediators; reported by Kawada N., 1999; Malik et al., 2002; 
Davis et al., 1996; Cruz-Gervis et al., 2002; Kawada et al., 1992; Fisher et al., 1987) or 
suppressing (anti-fibrogenic mediators; reported by Ju et al., 2002; Dieter, 1996; Davis, 1997; 
Kawada et al., 1992) the further development of liver inflammation and fibrogenesis.  
 
Fig. 1.5. 
Fig. 1.5. The development of liver fibrosis is under control of pro- and anti-fibrogenic 
substances
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1.3. Purpose of study 
 
 
 
The present study is focused on the synthesis of inflammatory mediators (PGE2, TxA2, NO, 
interleukins) by liver macrophages under inducible conditions. The released products promote 
(IL-1β, TNFα, TxA2) or abrogate (PGE2, NO, IL-10) the liver injury. The reciprocal action 
between anti- and pro-inflammatory mediators operates the wound’s trend. This work is 
therefore directed on the autocrine activation of macrophage by pro-inflammatory mediators 
which causes the enlarged production of protective substances and delays the further 
development of inflammation. 
Firstly, the purpose of study is the investigation of prostanoid (PGE2 and TxA2) release in 
vitro upon stimulation and a long period of incubation and the characterization of enzymes 
involved in their synthesis. Furthermore, the coupling of cPLA2, COX isoenzymes and PGE2 
synthases is characterized.  
Secondly, the presented study evaluates the autocrine effect of pro-fibrogenic and anti-
fibrogenic cytokines on prostanoid production.  
Thirdly, the transcriptional and translational regulation of NO synthesis in liver macrophages 
and the interaction between prostanoids and NO is investigated.  
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2. MATERIALS AND METHODS 
 
 
2.1. Materials 
 
2.1.1. Equipment and materials 
 
2.1.1.1. Instruments 
 
Automated gel analysis system „GeneGenius“ Syngene (Cambridge, UK) 
  
Centrifuges:  
Beckman J2-21M/E high-speed 
centrifuge 
Beckman Instruments (Munich, Germany) 
         Beckman Ultracentrifuge Optima TL-100 Beckman Instruments (Munich, Germany) 
         Eppendorf 5417 -R, -C Eppendorf (Hamburg, Germany) 
         Sigma 4K10 B. Braun (Melsungen, Germany) 
  
Color Scanner Umax PowerLook II Umax Systems GmbH (Willich, Germany) 
EHRET Biosafe ET 130/KI2 Ehret GmbH & Co. KG (Emmendingen, Germany) 
Electric balance „BP2100S“ Sartorius AG (Göttingen, Germany) 
Electric balance „Analytic AC120S“ Sartorius AG (Göttingen, Germany) 
  
Electrophoresis chambers:  
         Horisontal, „Agagel maxi” Biometra (Göttingen, Germany) 
         Horisontal, „Mini”, “Midi” Harnischmacher-Labortechnik (Kassel, Germany) 
          Verical SE600  Hoeffer Scientific Instruments (San Francisco, CA, 
USA) 
          Verical Bio-Rad Mini  Cell Bio-Rad Laboratories (Munich, Germany) 
  
Electrophoresis power supply:  
         Standard Power Pack P25 Biometra® (Göttingen, Germany) 
         Power Pac 3000 Bio-Rad Laboratories (Munich, Germany) 
         Mini Protean II Bio-Rad Laboratories (Munich, Germany) 
  
High performance chemiluminescence’s 
system “Genegnome” 
Syngene (Cambridge, UK) 
Gilson Pipetman Pipette Gilson International B.V. (DEN HAAG The 
Netherlands) 
Gradient former Model 385 Bio-Rad Laboratories (Munich, Germany) 
Incubator Heraeus BS 6000 Heraeus Med GmbH (Hanau, Germany) 
Laminar downflow cabinet Faster LS90 model 
„TWO30” 
Faster Bio-Flow-Technik (Germany) 
Magnetic stirrer and temperature controller 
Heidolph MR 2002 
Heidolph (Kehlheim, Germany) 
  
Microscopes:  
         Zeiss Microscipe Carl Zeiss (Göttingen, Germany) 
         Mikroscope Wilovert S Hund GmbH (Germany) 
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Microwave Oven AEG Micromat AEG (Nuernberg, Germany) 
Milli-Q-Plus PF water purification system Millipore (Eschborn, Germany) 
Mini TransBlot Electrophoretic Transfer Cell Bio-Rad (Italy) 
Minishaker MS2 IKA® IKA Works, Inc. (Wilmington, NC, USA) 
Osmometer Vogel Digital, OM-802 Vogel GmbH (Giessen, Germany) 
Orbital incubator “Innova 4330” New Brunswich Scientific GmbH (Germany) 
  
PCR thermocyclers:  
Perkin Elmer GeneAmp PCR System 
Model 2400 
PerkinElmer Life Sciences (Boston, MA, USA)  
         Mastercycler®/ Mastercycler® Gradient Eppendorf GmbH (Hamburg, Germany) 
  
Peristaltic pump MasterFlex Digi-Staltic Model 
7525-36 
Cole-Parmer Instrument Company (Barrington, IL, 
USA) 
pH-Meter Knick model 763 Multi-Calimatic Knick Elektronische Messgerate (Berlin, Germany) 
Pipetting support: Pipettus Accu®  Hirschmann Laborgeräte (Eberstadt, Germany) 
Plate reader Dynatech MRX Dynatech Laboratories Ltd. (Billingshurst, UK) 
Reagent glass shaker Reax 2000 Heidolph (Germany) 
  
Spectrophotometers:  
NanoDrop® ND-1000 UV-Vis    
Testimonial 
G.Kisker GbR (Steinfurt, Germany) 
         LKB Pharmacia Ultrospec III UV/VIS  Pharmacia LKB Biochrom (Cambridge, UK) 
         Shimadzu UV-Mini 1240 UV-Vis Shimadzu Deutschland GmbH (Duisburg, Germany) 
  
Termomixer Comfort Eppendorf (Hamburg, Germany) 
Ultrasonic cleaner Bandelin Sonorex RK100 Bandelin GmbH (Berlin, Germany) 
Ultrasonic homogenizer Sonopuls HD-70  Bandelin GmbH (Berlin, Germany) 
Waterbath Grant Sub 6 Grant (Cambridge, UK) 
 
 
2.1.1.2.Equipment 
 
26-gauge spinal needle B. Braun (Melsungen, Germany) 
Cell scraper Greiner Bio-One GmbH (Frickenhausen, Germany) 
Centrifuge conic tubes 15 cm2, 50 cm2 Greiner Bio-One GmbH (Frickenhausen, Germany) 
Cellulose-acetate sheets Schleicher und Schöll (Dassel, Germany) 
Injekt 40 syringe B. Braun (Melsungen, Germany) 
Neubauer cell counting chamber Paul Marienfeld GmbH (Bad Mergentheim, Germany) 
Nylon Net Filter roll hydrophilic 100 µm Millipore (Eschborn, Germany) (#NY1H00010) 
Nitrocellulose membrane Hybond™-c Amersham Life Science (Beckingham, UK) (#RPN303E) 
Parafilm American National Can (Greenwich, CT, USA) 
PCR Reaction tubes Greiner Bio-One GmbH (Frickenhausen, Germany) #671272-7 
Safe-Lock Tubes 0.5-2 ml Eppendorf (Hamburg, Germany) 
Pipette tips Greiner Bio-One GmbH (Frickenhausen, Germany) 
Tissue culture dish, Falcon 3001 Ø 35 
mm  Becton Dickinson (Franklin Lakes, NJ, USA) 
X-ray films Amersham Life Science (Beckingham, UK) 
96 well plate Greiner Bio-One GmbH (Frickenhausen, Germany), Nunc (Roskilde, Denmark) 
 
 
 
II. Materials and methods                                                       26 
   
2.1.1.3. Animals 
 
Male Wistar rats  Charles River (Sulzfeld, Germany) 
 
 
2.1.1.4. Special software for molecular biology 
 
ImageQuaNT® 5.0 Molecular Dynamics®/Amersham Biosciences 
GeneSnap 3.00.25 Syngene (Cambridge, UK) 
NanoDrop 2.5.4 G.Kisker GbR (Steinfurt, Germany) 
Primer3 Whitehead Institute for Biomedical Research
 
(Rozen S. et al., 2000) 
BLAST (NCBI) 
National Center for Biotechnology Information 
(Bethesda, MD, USA) 
(Madden et al., 1996; Zhang et al., 2000) 
 
 
 
2.1.2 Chemicals 
 
All buffers and solutions are made in sterile H2O, prepared by Milli-Q-Plus PF water 
purification system unless otherwise stated. 
 
 
Table 2.1. Chemicals 
Substances Company Catalog No. 
A23187, free acid (C29H37N3O6) Calbiochem/Merck Biosciences GmbH (Bad Soden, 
Germany) 
#100105 
ABTS Roche Diagnostic GmbH (Mannheim, Germany) #102946 
Acetic acid Merck KG (Darmstadt, Germany) #1.00063.1011 
Acetylsalicylic acid Sigma (Deisenhofen, Germany) #A-5376 
Acetone Karl Fischer Reagents #NT 2000 
Acrylamide/Bis Bio-Rad Laboratories (Munich, Germany)  #161-0120 
Agarose Serva (Heidelberg, Germany) #11400 
Amido Black 10B Merck KG (Darmstadt, Germany) #1167 
Ammonium persulfate  Bio-Rad Laboratories (Munich, Germany)  #161-0700 
Aprotinin, 10 mM solution Sigma (Deisenhofen, Germany) #A-6279 
Benzamidin Sigma (Deisenhofen, Germany) -6506 
Boric acid Merck KG (Darmstadt, Germany) #1.00165.1000 
Bromophenol Blue Fluka AG (Buchs, Switzerland) #18030/040 
CaCl2  Merck KG (Darmstadt, Germany) #102083 
Carbogen (95% O2/5% CO2) Messer Griesheim (Krefeld, Germany)  
Chloroform Sigma (Deisenhofen, Germany) #C-5312 
Citric acid Merck KG (Darmstadt, Germany) #241 1000 
Coomassie® Brilliant Blue G250 Bio-Rad Laboratories (Munich, Germany) #161-0400 
DEPC Sigma (Deisenhofen, Germany) #D-5768 
Dithiotheriol Sigma (Deisenhofen, Germany) #D-0632 
DMSO Calbiochem #317275 
dNTP’s Invitek GmbH (Berlin, Germany) #30203012 
EDCI IRIS Biotech GmbH (Marktredwitz, Germany) #RL-1022 
EDTA Sigma (Deisenhofen, Germany) #E5134 
EGTA Sigma (Deisenhofen, Germany) #E-3889 
Ethanol Merck KG (Darmstadt, Germany) #11727 
 Continued on next page 
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Table 2.1. (continued from page 26) 
Substances Company Catalog No. 
Ethidium bromide Sigma (Deisenhofen, Germany) #E-1510 
Ficoll 400 Sigma (Deisenhofen, Germany) #F-4375 
Fast Green BDH Chemicals Ltd. (Poole, UK) #42053 
FeCl2 Sigma (Deisenhofen, Germany) #F-2130 
Formic acid Sigma (Deisenhofen, Germany) #251364 
Formaldehyde Sigma (Deisenhofen, Germany) #F-1268 
Formamide Merck KG (Darmstadt, Germany) #12027 
Glacial acetic acid Sigma (Deisenhofen, Germany) #338826 
Glucose Merck KG (Darmstadt, Germany) #K2164137 309 
Glycine ICN Biomedicals (Eschwege, Germany) #808822 
Glycerol ICN Biomedicals (Eschwege, Germany) #800688 
Guanidine hydrochloride Merck KG (Darmstadt, Germany) #12031 
HCl Merck KG (Darmstadt, Germany) #1.00317.1000 
Hepes Sigma (Deisenhofen, Germany) #7365-45-91 
Isopropyl alcohol Sigma (Deisenhofen, Germany) #I-9516 
KCl Fluka AG (Buchs, Switzerland) #60132 
KH2PO4 Merck KG (Darmstadt, Germany) #104873 
K2HPO4 . 3H2O Merck KG (Darmstadt, Germany) #105099 
MgCl2 . 6H2O Sigma (Deisenhofen, Germany) #M-0250 
MgSO4 . 7H2O Merck KG (Darmstadt, Germany) #105886 
Methanol Merck KG (Darmstadt, Germany) #1.06009.1011 
β-Mercaptoethanol Sigma (Deisenhofen, Germany) #M-7154 
Milk powder Bio-Rad Laboratories (Munich, Germany) #170-6404 
MOPS Sigma (Deisenhofen, Germany) #M-8893 
Na-acetat Sigma (Deisenhofen, Germany) #S-8625 
Na2BO2 .  H2O2 . 3 H2O Merck KG (Darmstadt, Germany) #1.06560.1000 
NaCl Merck KG (Darmstadt, Germany) #1.06404.1000 
Na2EDTA Merck KG (Darmstadt, Germany) #1.06392.1000 
Na2CO3 Merck KG (Darmstadt, Germany) # 106392 
NaHCO3 Merck KG (Darmstadt, Germany) #106329 
NaNO2 Merck KG (Darmstadt, Germany) #106549 
NaOH Chemapol (Chech Republic) #500360388 
Na-thiosylfate Sigma (Deisenhofen, Germany) #S-1648 
N-(1-Naphthyl)-ethylenediamine 
dihydrochloride 
Sigma (Deisenhofen, Germany) #N-9125 
Na-vanadat Sigma (Deisenhofen, Germany) #S-6508 
Nycodenz Axis-Shiels PoC AS (Oslo, Norvay) #1002424 
Phenobarbital Nembutal™ Sigma (Deisenhofen, Germany) #P-3636 
Phenol Red Sigma (Deisenhofen, Germany) #P-0290 
Peroxidase-conjugated Streptavidin Dianova (Hamburg, Germany) #016-030-084 
PMSF Sigma (Deisenhofen, Germany) #P-7626 
Phosphoric acid (conc.) Merck KG (Darmstadt, Germany) #1.00573.1000 
Sodium dodecil sulphate Bio-Rad Laboratories (Munich, Germany) #161-0302 
Sulfanilamide              C6H8N2O2S Sigma (Deisenhofen, Germany) #S-9251 
Sucrose Serva (Heidelberg, Germany) #35579 
Sulfo-NHS Sigma (Deisenhofen, Germany) #56485 
TCA                               C2HCl3O2 Sigma (Deisenhofen, Germany) #522082 
TEMED Bio-Rad Laboratories (Munich, Germany) #161-0800 
Tris-HCl Merck KG (Darmstadt, Germany) #108219 
Triton X-100 Sigma (Deisenhofen, Germany) #9002-93-1 
Trypan Blue Solution 0.4% Sigma (Deisenhofen, Germany) #T-8154 
Tween 20 Serva (Heidelberg, Germany) #37470 
Urea ICN Biomedicals (Eschwege, Germany) #821527 
Xylene cyanol Sigma (Deisenhofen, Germany) #X-4126 
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2.1.2.1. Commercial reagents and kits 
 
Table 2.2. Commercial reagents and kits 
Reagent/Kit Company Catalog No. 
Bichinonic acid protein assay kit Sigma (Deisenhofen, Germany) CA-1, B9643 
Bio-Rad Protein Assay Bio-Rad Laboratories (Munich, Germany) #500-0006 
   
Bovine serum albumin Serva (Heidelberg, Germany) #11925, 
#11930 
Cytotoxicity Detection Kit Merck KG (Darmstadt, Germany) #1 644 793 
High Pure PCR Product Purification Kit Roche Diagnostic GmbH (Mannheim, 
Germany) 
#1 732 668 
LumiGLO® Reagent and Peroxide Cell Signaling Technology, Inc. (Beverly, 
MA, USA) 
#7003 
Oligo (dT)15 Primer Promega (Mahnheim, Germany) #C1101 
Fluoresbrite™ calibration grade 1.0 
micron YG Microspheres (2.66% Solids 
latex) 
Polysciences Inc. (Warrington, PA, USA) #18860 
QIAshredder spin columns Quiagen (Hildesheim, Germany) #79656 
Recombinant RNasin Ribonuclease 
inhibitor 
Promega (Mahnheim, Germany) #N2511 
RNase-Free-DNAse Set Quiagen (Hildesheim, Germany) #79254 
RNeasy kit Quiagen (Hildesheim, Germany) #74106 
Invitrogen Life technologies (Karlsruhe, 
Germany) 
#18053-017 SuperScript RNase H- Reverse 
Transcriptase, 1st Strand Buffer 
Gibco (Karlsruhe, Germany) # 18064-022 
Taq DNA polymerase, PCR Buffer Promega (Mahnheim, Germany) #M1865 
Taq DNA polymerase, PCR Buffer Invitrogen Life technologies (Karlsruhe, 
Germany) 
#10342-020 
TRIzol LS Reagent (NEW)  Invitrogen Life technologies (Karlsruhe, 
Germany) 
#10296-028 
 
 
 
2.1.2.2. Antibiotics 
 
Penicillin G. K-salt Serva (Heidelberg, Germany) #31749 
Streptomycin sulfate  Serva (Heidelberg, Germany) #35500 
 
 
2.1.2.3. Enzymes 
 
Table 2.3. Enzymes 
Enzyme Company Catalog No. 
Catalase Sigma (Deisenhofen, Germany) #C-9322 
Collagenase (CLS) Seromed-Biochem KG (Berlin, Germany) #C-1-22 
DNAse I from Bovine pancrease Boehringer Mannheim  (Mannheim, Germany) #1284932 
Pronase from Clostridium hislyticum  Roche Diagnostic GmbH (Mannheim, Germany) #1 213 865 
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2.1.2.4. Cell culture media 
 
 
Table 2.4. Cell culture media 
Media Company Catalog No. 
RPMI medium Biochrom AG (Berlin, Germany) #T 127-50 
Newborn calf serum Biochrom AG (Berlin, Germany)  
Fetal calf serum BoiWest (Nuaillé, France)  
Hanks Biochrom AG (Berlin, Germany) #L201-05 
DMEM Biochrom AG (Berlin, Germany) #F 0405 
 
 
 
 
 
2.1.2.5. Stimuli 
 
Table 2.5. Substances used for cells stimulation 
Stimulus Company Catalog 
No. 
Dexamethasone Calbiochem/Merck Biosciences GmbH (Bad Soden, 
Germany) 
#265005 
Indomethacine Sigma (Deisenhofen, Germany) #I-7378 
L-NIL Calbiochem/Merck Biosciences GmbH (Bad Soden, 
Germany) 
#482100 
L-NMMA Calbiochem/Merck Biosciences GmbH (Bad Soden, 
Germany) 
#475886 
LPS (Salmonella Minnesota, 
R595) 
Gift from Dr. Galanos (Freiburg, Germany) --- 
PGE2 Sigma (Deisenhofen, Germany) #P0409 
PGH2 Cayman Chemical Company (Ann Arbor, Michigan, USA) #17020 
Recombinant rat IL-1β R&D Systems (Wiesbaden, Germany) #501-RL 
Recombinant rat IL-6 R&D Systems (Wiesbaden, Germany) #506-RL 
Recombinant rat IL-10 R&D Systems (Wiesbaden, Germany) #522-RL 
Recombinant rat TNFα R&D Systems (Wiesbaden, Germany) #510-RT 
SC-236 Searle, Monsanto Co. (St Louis, MO, USA)  
SC-560          Searle, Monsanto Co. (St Louis, MO, USA)  
SNAP Calbiochem/Merck Biosciences GmbH (Bad Soden, 
Germany) 
#487910 
Zymosan A. (Sacc. Cerevisiae) Sigma (Deisenhofen, Germany) #Z-4250 
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2.1.2.6. Antibodies 
 
2.1.2.6.1. Primary antibodies for Western blot 
 
Table 2.6. Primary antibodies for Western blot 
Antibodies Origin 
of 
antigen 
Clon
(Poly/
Mono)
Host Catalog 
No. 
Company Used 
dilutions
Mr* 
Anti-5-Lipoxygenase Human Poly. Rabbit #160402 Cayman Chemical Company (Ann Arbor, Michigan, USA) 1:1 000 78 
Anti-actin Mouse Mon.. Mouse #A5316 Sigma-Aldrich Chemie Gmbh (Munich, Germany) 
1 :500 
1 :2 500 42 
Anti-COX-1 Murine Poly. Rabbit #160109 Cayman Chemical Company (Ann Arbor, Michigan, USA) 1:2 000 70 
Anti-COX-2 Murine Poly. Rabbit #160126 Cayman Chemical Company (Ann Arbor, Michigan, USA) 1:500 72 
Anti-cPLA2 Murine Poly. Rabbit #PL 05 
Oxfrod Biomedical research 
(Oxford, MI, USA), Natutec 
GmbH (Frankfurt am Main, 
Germany) 
1:1 000  
Anti-EP1 Receptor Human Poly. Rabbit #101740 
Cayman Chemical Company 
(Ann Arbor, Michigan, USA) 
1:500 
1:1 000 42 
Anti-EP2 Receptor Human Poly. Rabbit #101775 
Cayman Chemical Company 
(Ann Arbor, Michigan, USA) 
1:500  
1:1 000 52 
Anti-EP3 Receptor Human Poly. Rabbit #101760 
Cayman Chemical Company 
(Ann Arbor, Michigan, USA) 
1:500 
1:1 000 53 
Anti-EP4 Receptor 
(C-term) Human Poly. Rabbit #101775 
Cayman Chemical Company 
(Ann Arbor, Michigan, USA) 
1:500 
1:1 000 52 
Anti-iNOS/NOS 
Type II Mouse Mono. Mouse #610599 
BD Transduction Laboratories 
(San Jose, CA, USA)  130
Anti-mPGES-1 Human Poly. Rabbit #160140 Cayman Chemical Company (Ann Arbor, Michigan, USA) 1:500  16 
Anti-mPGES-2 Human Poly. Rabbit #160145 Cayman Chemical Company (Ann Arbor, Michigan, USA) 1:200 33 
Anti-PGES 
(cytosolic) Human Poly. Rabbit #160150 
Cayman Chemical Company 
(Ann Arbor, Michigan, USA) 1:250 23 
Anti-PGES 
(cytosolic) Human Poly. Rabbit -- 
1) 1:250 
1:1 000 23 
Anti-PGDS Rabbit Poly. Rat -- 2) 1:1 000 263)
Anti-PGF2αS (lung 
type) Human Poly. Rabbit -- 
4) 1:2 000 375)
Anti-PGF2αS (liver 
type) Cow Poly. Rabbit -- 
4)  1:2 000 376)
Anti-Phospho-cPLA2 
(Ser505) Human Poly. Rabbit #2831 
Cell Signaling Technology, 
Inc. (Beverly, MA, USA) 1:1 000 110
Anti-TxAS Human Poly. Rabbit #160715 Cayman Chemical Company (Ann Arbor, Michigan, USA) 1:1 000 60 
*Molecular weight or relative mobility on SDS-PAGE (after producer’s data) 
 
 
 
 
 
1) Antibodies were kindly provided by Murakami M. (Japan) 
2) Antibodies were kindly provided by Kanaoke and Urade (Japan) 
3) Urade et al., 1987 
4) Antibodies were kindly provided by Watanabe K. (Japan) 
5) Suzuki-Yamamoto et al., 1999a 
6) Suzuki-Yamamoto et al., 1999b 
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2.1.2.6.2. Primary antibodies for ELISA 
 
Table 2.7. Primary antibodies for ELISA 
Antibodies Origin of antigen Stock solution 
Anti-PGE2 Mouse 1 mg/ml in H2O 
 
 
2.1.2.6.3. Secondary antibodies 
 
Table 2.8. Secondary antibodies for Western blot and ELISA 
Antibodies Origin of 
antigen 
Host Catalog No. Company Used dilutions 
Anti-Biotin HRP-linked Biotin Goat #7075 Cell Signaling Technology, Inc. (Beverly, MA, USA) 1 :10 000 
Anti-Mouse HRP-linked Mouse Horse #7076 Cell Signaling Technology, Inc. (Beverly, MA, USA) 1:2 000 
Anti-Rabbit HRP-linked Rabbit Goat #7074 Cell Signaling Technology, Inc. (Beverly, MA, USA) 1:2 000 
Anti-Mouse Biotin-SP-
conjugated Mouse Goat 
#515-065-
062 Dianova (Hamburg, Germany) 1:5 000 
 
 
2.1.2.7. SDS-PAGE and DNA Standards 
 
Table 2.9. SDS-PAGE and DNA Standards 
Marker Company Catalog No. 
pqGOLD 50bp DNA-marker Peqlab Biotechnologie (Erlangen , Germany) #25-2001 
RNA Molecular Weight Marker III Roche Diagnostic GmbH (Mannheim, 
Germany) 
#1062638 
Biotinylated SDS-PAGE Standards, Low 
Range 
Bio-Rad Laboratories (Munich, Germany) #161-0306 
Biotinylated SDS-PAGE Standards, 
HighRange 
Bio-Rad Laboratories (Munich, Germany) #161-0311 
Biotinylated SDS-PAGE Standards, 
Broad Range 
Bio-Rad Laboratories (Munich, Germany) #161- 0319 
Prestained SDS-PAGE Standards, Low 
Range 
Bio-Rad Laboratories (Munich, Germany) #161-0305 
Prestained SDS-PAGE Standards, 
HighRange 
Bio-Rad Laboratories (Munich, Germany)  #161-0309 
Prestained SDS-PAGE Standards, Broad 
Range 
Bio-Rad Laboratories (Munich, Germany)  #161- 0318 
 
2.1.2.8. Blocking peptide 
 
Table 2.10. Blocking peptide for Western blot 
Peptide Company Catalog 
No. 
cPGES Blocking peptide  Cayman Chemical Company (Ann Arbor, Michigan, USA) #360150 
EP1 Blocking peptide  Cayman Chemical Company (Ann Arbor, Michigan, USA) #301740 
EP2 Blocking peptide  Cayman Chemical Company (Ann Arbor, Michigan, USA) #301750 
EP3 Blocking peptide  Cayman Chemical Company (Ann Arbor, Michigan, USA) #301760 
EP4 (C-term) Blocking peptide  Cayman Chemical Company (Ann Arbor, Michigan, USA) #301775 
TxAS Blocking peptide  Cayman Chemical Company (Ann Arbor, Michigan, USA) #360715 
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2.1.2.9. Oligonucleotide primers 
 
All primers are purchased from MWG Biotech (Ebersberg, Germany). 
 
Table 2.11. Oligonucleotide primers for PCR 
Target 
mRNA 
Sequence GenBank 
accession No 
Expect. 
PCR 
product 
size, bp 
Conditi
ons of 
PCR: 
Tann/N 
So-
urc
e 
β-actin 
Forward 5’- GTGGGGCGCCCCAGGCACCA -3’, 
Reverse 5’- CTCCTTAATGTCACGCACGATTTC -3’ 
NM_001101 540 60°C/ 
30 cycles 
1) 
COX-1 
Forward 5’- TGCATGTGGCTGTGGATGTCATCAA -3’ 
Reverse 5’- CACTAAGACAGACCCGTCATCTCCA -3’ 
NM_008969  
NM_017043 450 
60°C/ 
35 cycles 1) 
COX-2 
Forward 5’-ACTCACTCAGTTTGTTGAGTCATTC-3’ 
Reverse 5’-TTTGATTAGTACTGTAGGGTTAATG-3’ 
NM_011198   
S67772 583 
55°C/ 
35 cycles 1) 
cPGES 
Forward 5’- CCAAATGATTCCAAGCATAAAAGAA -3’ 
Reverse 5’- TTCTGGTAAATCTACATCCTCATCA -3’ 
AY281130   
BC085264 240 
60°C/ 
30 cycles 2) 
cPLA2 
Forward 5’-CTTACGCCACAGAAAGTTAAAAGAT-3’, 
Revesre 5’-TCCAAACAAGTCAGGAGTCATAAA -3’  
S77829.1 309 60°C/ 
30 cycles 1) 
eNOS I 
Forward 5’-AGACGGACCCAAGTTTCCTC -3’ 
Reverse 5’-TGATGGCTGAACGAAGATTG -3’ 
AF085195 497 60°C/ 
30 cycles 3) 
eNOS II 
Forward 5’- GGAGAAGATGCCAAGGCTGCTG-3’ 
Reverse 5’-CTTCCAGTGTCCAGACGCACCA -3’ 
U02534   
XM_216065 224 
65°C/ 
30 cycles 4) 
GFAP 
Forward 5’- ACATCGAGATCGCCACCTAC -3’ 
Reverse 5’- ACATCACATCCTTGTGCTCC -3’ 
NM_017009 219 60°C/ 
30 cycles 
5) 
iNOS 
Forward 5’- GCTTGCCCCTGGAAGTTTCTC -3’ 
Reverse 5’- CCGACCTGATGTTGCCACTGT -3’ 
AY211532 
D12520 D14051 
D44591 
NM_012611 
U26686 X76881 
710 60°C/ 
30 cycles 1) 
mPGES-1 
Forward 5’- CCCAGGTAGGCCACGGTGTGT -3’ 
Reverse 5’- CTGCTGGTCATCAAGATGTACG -3’ 
AB041998   
AB048730   
AF280967   
NM_021583 
292 60°C/ 
30 cycles 6) 
mPGES-2 
Forward 5’- ATATTGTCCGTGAGGGCAAG -3’ 
Reverse 5’- TACACTGCCAGGTCAGCAAG -3’ 
XM_231144 226 59°C/ 
32 cycles 7) 
nNOS 
Forward 5’- CTTGGTAGACCTCAGCTATGA -3’ 
Reverse 5’- TGCCATCGAGGTCTCTGTCCA -3’ 
NM_052799   
U67309   X59949 514 
63°C/ 
35 cycles 4) 
PGDS 
Forward 5’- GTTTTGGAGGTGGAAGGACT -3’ 
Reverse 5’- CCAATAGAAATCTGCCCAAG -3’ 
AF021882   
D82071    
NM_031644 
303 57°C/ 
35 cycles 1) 
PGF2α 
Forward 5’- CATTGCTATGGAAGAGTCAACA -3’ 
Reverse 5’- CCTGTCCTTCTGAAAAGATGTG -3’ 
AA859039 314 60°C/ 
35 cycles 1) 
TxAS 
Forward 5’- ACCCAAGCTGATAGCAGACA -3’ 
Reverse 5’- GTGACCATGTCAAAGGCTTC -3’ 
D28773   D 31798   
NM_012687 555 
67°C/ 
35 cycles 1) 
      
1) Unpublished (designed by 
Schade S.) 
2) Generous gifts from Lazarus M. 
3) Miethke et al., 2003 
4) Gilchrist et al., 2002 
5) Belanger et al., 2002 
6) Lazarus et al., 2002b 
7) Unpublished (designed by Bezugla Y.) 
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2.1.3. Buffers and solutions 
 
 
2.1.3.1. Solutions for Kupffer cells primary culture 
 
 
All buffers and solutions, used for Kupffer cells culture, are steril filtered prior to use. In preparations 
involving the isoosmotic solutions, the osmolality is determined by cryoscopy with a freezing point 
depression osmometer. The osmolality is adjusted to 275-300 mOsm/kg water by adjustment/reducing 
of sodium chloride. 
 
 
 HBSS, modified, Ca2+/Mg2+-free (pre-prfusion buffer): 
 
5.4 mM KCl 
0.38 mM KH2PO4 
122 mM NaCl 
4.2 mM NaHCO3 
0.34 mM Na2HPO4 . 2 H2O 
10 mM D-Glucose . 1 H2O 
 
pH 7.4 (saturated by 95% O2 and 5% CO2), steril; 
 
 
 Hanks’ Balanced Salt solution (HBSS), modified (perfusion buffer): 
 
1.3 mM CaCl2 . 2 H2O 
5.4 mM KCl 
0.38 mM KH2PO4 
0.4 mM MgSO4 . 7 H2O 
122 mM NaCl 
4.2 mM NaHCO3 
0.34 mM Na2HPO4 . 2 H2O 
10 mM D-Glucose . 1 H2O 
  
1 mM Phenol Red 
 
pH 7.4 (by NaOH), osmolality 275-295 mOsm/kg water, steril; 
 
 
 HBSS, modified, NaCl-free: 
 
1.3 mM CaCl2 . 2 H2O 
5.4 mM KCl 
0.38 mM KH2PO4 
0.4 mM MgSO4 . 7 H2O 
4.2 mM NaHCO3 
0.34 mM Na2HPO4 . 2 H2O 
10 mM D-Glucose . 1 H2O 
 
pH 7.4 (by NaOH), steril; 
 
 
 
 
II. Materials and methods                                                       34 
   
 Hanks medium, with HEPES: 
 
1.3 mM CaCl2 . 2 H2O 
5.4 mM KCl 
0.38 mM KH2PO4 
0.4 mM MgSO4 . 7 H2O 
0.5 mM MgCl2 . 6 H2O 
122 mM NaCl 
0.34 mM Na2HPO4 . 2 H2O 
10 mM D-Glucose . 1 H2O 
20 mM HEPES 
 
pH 7.4, steril; 
 
 
 RPMI culture medium: 
  
1.03 % (w/v) RPMI 1640 
0.0065 % (w/v) Penicillin 
0.01 % (w/v) Streptomycin 
0.2 % (w/v) NaHCO3 
 
pH 7.3 (by HCl conc.), osmolality 275-285 mOsm/kg water, steril; 
 
 
 PBS: 
138 mM NaCl 
2.68 mM KCl 
7.3 mM Na2HPO4 . 2 H2O 
1.47 mM KH2PO4 
 
pH 7.4 (by 1M HCl), steril; 
 
 
2.1.3.2. Solutions for ELISA 
 
 
 NaHCO3/EDTA-solution: 
 
2 % (w/v) NaHCO3 
100 mM EDTA 
 
 ELISA Conjugation solution: 
 
0.2 % (w/v) BSA 
7.5 µM ECDI 
0.01 mM Sulfo-NHS 
 
 ELISA Buffer I: 
 
0.05 M NaHCO3 
0.05 M Na2CO3 
 
pH 6.9 (by 0.05 M Na2CO3), prepared immediately before use; 
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 ELISA Buffer II: 
 
0.1 % (w/v) BSA 
  PBS 
 
Prepared immediately before use; 
 
 ELISA Washing Buffer: 
 
0.9 % (w/v) NaCl 
5 mM Tris 
0.05 % (w/v) Tween 20 
 
pH 7.4; 
 
 ELISA Substrate’s solution 
 
60 mM Na2HPO4 . 2 H2O 
39 mM Citric acid 
2 mM ABTS 
3.25 mM Na2BO2 .  H2O2 . 3 H2O 
pH 4.5, fresh prepared; 
 
 
 
2.1.3.3. Solutions for protein lysate preparations 
 
 
 Cell Lysis Buffer (for total protein extraction): 
 
10 mM Tris-HCl 
150 mM NaCl 
2 mM EDTA 
1 % (w/v) Triton X-100 
   
0.1 mM Aprotinin 
1 mM Na-orthovanadat 
1 mM PMSF (stock solution is prepared using iso-propanol) 
1 mM PMSF 
10 mM Benzamidin 
 
 
 Cell Lysis Buffer (for cytosolic/membrane protein extraction) (after Ways et al., 1992): 
 
20 mM Tris-HCl 
10 mM EDTA 
5 mM EGTA 
   
0.1 mM Aprotinin 
1 mM Na-orthovanadat 
1 mM PMSF (stock solution is prepared using iso-propanol) 
1 mM PMSF 
10 mM Benzamidin 
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 Cell Lysis Buffer (with sucrose (after Stichtenoth et al., 2001), for cytosolic/membrane protein 
extraction): 
 
0.1 M K2HPO4 . 3H2O 
0.1 M KH2PO4 
1 mM EDTA 
0.25 M Sucrose 
   
0.1 mM Aprotinin 
1 mM Na-orthovanadat 
1 mM PMSF (stock solution is prepared using iso-propanol) 
10 mM Benzamidin 
 
 
All Cell Lysate Buffers are stored for 4 weeks at 4°C; aprotinin, Na-orthovanadat and benzamidin are 
added prior to use. 
 
2.1.3.4. Solutions for determination of protein concentration 
 
 
 Amido Black Assay Staining Solution: 
 
0.5 % (w/v) Amido Black 10B 
45  % (v/v) Methanol 
10  % (v/v) Glacial acetic acid 
45  % (v/v) H2O 
 
 Amido Black Assay Washing Buffer: 
 
47.5 % (v/v) Methanol 
5 % (v/v) Glacial acetic acid 
47.5 % (v/v) H2O 
 Amido Black Assay Dissolution Buffer: 
 
80 % (v/v) Formic acid 
10 % (v/v) Glacial acetic acid 
10 % (v/v) TCA 
 
 
2.1.3.5. Solutions for SDS-PAGE 
 
 
 5 × SDS-Samples loading buffer 
 
0.3 M Tris-HCl, pH 6.8 
1.7 M SDS 
50 % (v/v) Glycerol 
0.1 % (w/v) Bromophenol Blue 
 
 
 Running buffer 
 
25 mM Tris-HCl 
192 mM Glycin 
0.05 % (w/v) SDS 
pH 8.2; 
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 Stacking gel (3%): 
 
3 % (w/v) Acrylamide/Bis 
125 mM Tris-HCl, pH 6.8 
0.1 % (w/v) SDS 
0.1 % (w/v) Ammonium persulfate 
0.06 % (vv) TEMED 
 
 Running gel (10% or 12%): 
 
10 or 12 % (w/v) Acrylamide/Bis  
(for 10% and 12% - gel respectively) 
375 mM Tris-HCl, pH 8.8 
0.1 % (w/v) SDS 
0.05 % (w/v) Ammonium persulfate 
0.05 % (vv) TEMED 
 
 Gradient Running gel solution I (5%): 
 
5 % (w/v) Acrylamide/Bis 
375 mM Tris-HCl, pH 8.8 
0.1 % (w/v) SDS 
0.04 % (w/v) Ammonium persulfate 
0.04 % (vv) TEMED 
 
 Gradient Running gel solution II (20%): 
 
20 % (w/v) Acrylamide/Bis 
375 mM Tris-HCl, pH 8.8 
0.1 % (w/v) SDS 
25 % (w/v) Glycerol 
0.04 % (w/v) Ammonium persulfate 
0.04 % (vv) TEMED 
 
 
 
2.1.3.6. Solutions for Western blot 
 
 Blotting buffer: 
 
50 mM Tris-HCl pH 8.2 
384 mM Glycin 
0.1 % (w/v) SDS 
20 % (v/v) Methanol 
 
 1 × TBS 
 
25 mM Tris-HCl pH 8.0 
150 mM NaCl 
 
 TBS-T 
 
  1 × TBS 
0.05 % (v/v) Tween-20 
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 Stripping buffer: 
 
62.5 mM Tris-HCl pH 6.8 
2 %(w/v) SDS 
10 mM β-Mercaptoethanol 
 
2.1.3.7. Solutions for proteins staining 
 
 Coomassie Staining solution: 
 
50 % (v/v) Methanol 
10 % (v/v) Acetic acid 
0.1 % (w/v) Coomassie® Brilliant Blue G250 
 
 Coomassie Destaining solution: 
 
30 % (v/v) Methanol 
7 % (v/v) Acetic acid 
 
 Fast Green Staining solution: 
 
0.1 % (w/v) Fast Green 
1 % (v/v) Acetic acid 
 
 
2.1.3.8. Solutions for agarose gel electrophoresis 
 
 10 × TBE: 
  
0.89 M Tris-HCl pH 8.3 
0.89 M Boric acid 
0.02 M EDTA 
 
 Agarose gel: 
  
2 % (w/v) Agarose 
 1 × TBE 
1 µg/m Ethidium Bromide 
 
 2 × Urea Gel Loading buffer 
 
2 × TBE 
13 % (w/v) Ficoll 400 
0.01 % (w/v) Bromphenol blue 
7 M Urea 
 
 5 × Gel Loading buffer I (modified after Klebe et al., 1999) 
 
0.01 % (w/v) Phenol red 
60 % (w/v) Sucrose 
 
 6 × Gel Loading buffer II 
 
15 % (w/v) Ficoll 400 
0.25 % (w/v) Bromphenol blue 
0.25 % (w/v) Xylene cyanol 
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2.2. Methods 
 
 
2.2.1. Kupffer cells primary culture 
 
2.2.1.1. Isolation of Kupffer cells from rat liver 
 
Primary cultures of Kupffer cells were obtained according to Eyhorn et al., 1988. 
All buffers and solutions, cell’s preparation and incubation, are steril filtered and pre-heated 
up to 37°C prior to use.  
 
2.2.1.1a. Isolation of non-parenchymal cells 
 
For KC isolation, the liver of male Wistar rats (500-600 g) is used. The animals are 
anaesthetized by Nembutal injection and the liver is aseptically removed. The portal vein is 
cannulated and the liver is perfused in situ with 450 ml HBSS Ca2+/Mg2+-free (pre-perfusion 
buffer) at 37.5 ml/min, 37°C in a non-recirculating system to remove blood. 
After the initial wash out the liver is transferred into the small keg and the recirculating 
perfusion ex situ (10 min) is initiated utilizing 70 ml of 0.5% (w/v) pronase in the HBSS 
(perfusion buffer, isoosmotic). The perfusate is constantly maintained at pH 7.4 using 
NaHCO3 saturated solution. After perfusate is sucked off, the next step of recirculating 
perfusion (15 min) is initiated utilizing 50 ml of 0,06% (w/v) collagenase and 0,02% (w/v) 
DNase in the HBSS (perfusion buffer). The liver is minced to small pieces and is incubated 
under constant agitation by magnetic stir bar at 37°C; the perfusate pH should be kept at 7.4 
by NaHCO3 saturated solution.  
Following digestion, the liver homogenate is transferred into the small Petri plate, debris are 
removed and the liver is combed out. The keg is rinsed by 70 ml of 0.1% pronase and 0.01% 
DNase in the HBSS (perfusion buffer) and the suspension is added to the liver. The resulting 
suspension is incubated under constant agitation at pH 7.4 (by NaHCO3 saturated solution) 
during 5-10 min. 
Undigested tissue is removed by filtration through a nylon mesh (100µm openings) in an ice-
cold beaker. Thereafter the suspension is filled up to 200 ml with HBSS Ca2+/Mg2+-free and 
distributed into 4 centrifuge tubes. 
The cells are harvested by centrifugation at 30 × g for 2 min at 4°C. The pellet is then 
suspended with HBSS Ca2+/Mg2+-free and the cells are sedimented by centrifugation at 500 × 
g for 8 min at 4°C (pellet I). The supernatant is dissolved with HBSS Ca2+/Mg2+-free and 
centrifuged at the same conditions (pellet II). The supernatant is discarded. 
 
 
2.2.1.1b. Preparations of non-parenchymal cell fractions 
 
To remove nonviable cells and to separate the different non-parenchymal cell types, a two-
phase density centrifugation is used. 
When the top phase is prepared, 43 ml of HBSS NaCl-free and 17 ml the 28.7% (w/v) 
Nycodenz (dissolved in HBSS NaCl-free) are mixed and divided between 6 centrifuge tubes. 
The bottom phase contains non-parenchymal cells suspension, prepared as following. Top 
layer of the cell pellet I and cell pellet II are carefully resuspended in the DMEM containing 
10% FCS and mixed with 11.8 ml of 57.4% (w/v) Nycodenz solution (in HBSS NaCl-free) 
and 2 mg DNase up to 40 ml. The suspension is divided into 4 centrifuge tubes (set A). The 
rest of cell pellet I is carefully resuspended in the DMEM containing 10% FCS and mixed 
with 5,9 ml of 57.4% (w/v) Nycodenz solution (in HBSS NaCl-free) and 1 mg DNase up to 
20 ml. The suspension is divided into other 2 centrifuge tubes (set B). 
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The double layer gradient formed is carefully overlaid with 10 ml of DMEM containing 10% 
FCS and centrifuged at 1350 × g for 25 min at 4°C without applying the centrifuge brake. 
After centrifugation, two layers are formed; one at the top of the 28.7%-gradient mostly 
containing HSC (they are mainly in the set A of tubes) and a second at the interface between 
the two gradients mostly containing viable hepatocytes and non-parenchymal cells of higher 
density (in both set A and B). The remaining pellet contains the majority of the 
enzymatically-injured hepatocytes. 
Top layer is collected as HSC and the volume is adjusted up to 35 ml by DMEM containing 
10% FCS. 
The interface is collected as cell’s mix, resuspended in RPMI containing 1% NCS and 
centrifuged at 500 × g for 8 min at 4°C. 
 
 
 
2.2.1.1c. Separation of Kupffer and endothelial cells by centrifugal elutriation 
 
 
Kupffer cells are further separated from viable hepatocytes and other sinusoidal cells by a 
modification of the centrifugal elutriation method originally described by Knook et al., 1977.  
The elutriation system consists of a J2-21/ME Beckman centrifuge with a JE-6B rotor 
equipped with a standard chamber (Beckman) and linked to a high precision peristaltic 
Masterflex pump. 
Before elutriation procedure, the pump is calibrated by H2O. Centrifuge, pump and 
connective hoses is sterilized by incubation for 30 min with 6% H2O2 following the 
incubation with aqueous 10% (w/v) Catalase solution (steril filtered) for 20 min and finally 
washing by aq. dest. 
The elutriation is performed at a rotor speed of 3250 rpm at 4°C. RPMI containing 1% NCS is 
used as elutriation medium. Cell suspension is loaded into the elutriation system at a 
peristaltic pump speed of 18.5 ml/min. 
After 200 ml of medium has passed through and a cell pellet is clearly formed into the 
elutriation chamber, the flow rate in the pump is increased stepwise from 18.5 to 60 ml/min 
and the correspondent volumes of cell suspension are collected at each point accordingly to 
Table 2.12.: 
 
 
 
Table 2.12. Parameters for centrifugal elutriation of cells    Table 2.12. 
Pump speed, ml/min Volume, ml Fractions//Cells 
18.5 200 Discard 
   
20.5 50 EC / 1st fraction 
24.5 50 EC / 2nd fraction 
27.5 50 EC / 3rd fraction 
   
32.0 100 Cells mixture // discard 
   
37.0 50 KC 1nd fraction 
43.0 50 KC 2nd fraction 
49.0 50 KC 3rd fraction 
55.0 50 KC 4th fraction 
50 KC 5th fraction > 60 50 KC 6th fraction 
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2.2.1.2. Kupffer cells primary culture 
 
For further purification the obtained cell population further, the method of selective adherence 
to plastic is used. The fractions 3-6 of Kupffer cells, that are found to contain the majority of 
KC, are centrifuged at 300 × g for 10 min at 4°C. The resulting pellets are collected together, 
washed in RPMI containing 1% NCS and centrifuged at 300 × g for 10 min at 4°C. The 
resulting pellet is suspended in 1 ml RPMI medium containing 1% NCS. 
The total cell total number and viability are determined by counting in Neubauer chamber 
using 0.2% Trypan blue solution (sock solution is diluted 1:2 by PBS): 50 μl of suspension is 
diluted 1:10 in the Trypan Blue solution and calculated as following: 
 
 
Nviable cells = A ∗ 104 ∗ 10 ∗ 1, 
 
 
where A – average number of cells counted in 1 mm2  field 
           104 – volume’s conversion factor for 1 mm2 
           10  -  dilution factor 
           1 – total volume of cell suspension 
Kupffer cells with viability higher of than 90% are used in experiments. 
Cells are then seeded on 35 mm Falcon’s plates at a density of 5∗106 cells/plate in 2 ml of 
RPMI medium containing 30% NCS. The cells are maintained in primary culture at 37°C in 
atmosphere with 5% CO2 for 24 h. Thereafter old medium with non-adherent cells is replaced 
by fresh medium and cells are incubated for 24 h at the same conditions. 
 
 
 
2.2.1.3. Identification of Kupffer cells 
 
Purity of KC is assessed by their typical light microscopic appearance, phagocytic activity and 
peroxidase staining.  
 
2.2.1.3a. Determination of phagocytic activity 
 
The ability of Kupffer cells to ingest fluorescent latex particles is assessed by measuring the 
cell-associated fluorescence. 
Kupffer cells are exposured to 0.0025% fluorescein-coupled latex particles (1 µm in diameter) 
for 30 min in at 37°C in Hanks medium. After the incubation cells are washed with PBS and 
the cell-associated fluorescence is detected by microscopy, the percentage of cells 
phagocytosing latex is calculated. 
 
 
2.2.1.3b. Peroxidase staining 
 
Kupffer cells are exposured to 0.05% (w/v) DAB in Hanks medium containing 0.03% H2O2 in 
at a pH value of 7.2 for 20 min at 37°C.  
The DAB-reacted Kupffer cells are washed 3 times in PBS to remove unreacted substrate and 
examined by microscope: Kupffer cells are brawn-black, endothelial cells and hepatocytes are 
colourless; erythrocytes are smaller, homogenous black cells. The percentage of Kupffer cells 
is calculated. 
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2.2.1.4. Stimulations of cells 
 
All experiments are performed with rat liver macrophages kept in primary culture in RPMI 
medium containing 30% NCS for 48 h.  
When the immediate response is envisaged, the culture medium is replaced by fresh Hanks 
medium containing the stimuli and cells are incubated for the indicated times (15 min to 1 h).  
Otherwise (if the long time incubation is explored) the culture medium is replaced by RPMI 
medium containing 10% NCS. In experiments required the short pre-treatment (15 min to 1 h) 
of cells, the cells are incubated for the indicated times in presence of the corresponding 
stimuli. Thereafter cell medium is replaced by fresh RPMI medium containing 10% NCS and 
the stimulus (or stimuli) required for the prolonged activation of cells. After indicated times 
(up to 24 h) of incubation supernatants are removed, centrifuged for 10 min at 16,000 × g at 
4ºC and, if not assayed immediately, frozen and kept at -20ºC. Cells are washed twice in 
sterile phosphate-buffered saline and RNA or protein lysate are prepared as described below. 
If immediate processing is not performed, cells are frozen in liquid nitrogen for the further 
preparation. 
Stimuli are provided in accordance to plan of experiment as following (Table 2.13.): 
 
 
 
 
 
Table 2.13. Dilutions of stock solutions for cell stimulation  Table 2.13. 
Stimulus Stock solution, storing 
temperature 
Dissolving Dilution in 
the medium, 
per plate  
Final 
concen-
tration 
A23187 10 mM in DMSO, -70 °C 1:10 in DMSO, 1:10 in Hanks 1:100 1 μM 
Dexamethasone 100 mM in DMSO, -20 °C 1:50 in DMSO, 1:20 in PBS 1:100 1 μM 
IL-1β 10 μg/ml, 4 °C 1:100 in PBS 1:100 1 ng/ml 
IL-6 0.157 mg/ml, 4 °C 1:100 in PBS 1:100 100 ng/ml 
IL-10 68 μg/ml, -20 °C 1:68 in PBS 1:100 10 ng/ml 
Indomethacine 10 μg/ml, -20 °C 1:100 in PBS 1:100 1 μM 
L-NMMA 50 mg/ml, -20 °C 1:50 in Aq. dest.  1:100 10 μg/ml 
L-NIL 100 mg/ml, -20 °C 1:38 in Aq. dest., 1:10 in Aq. dest. 1:100 10 μM 
LPS 1 mM, 4 °C 1:20 in Aq. dest 1:100 500 ng/ml 
PGE2 10 mM in Ethanol, -70 °C 1:100 in Aq. dest 1:100 1 μM 
SC-236 10 mM, -20 °C 1:100 in Aq. Dest 1:100 1 μM 
SC-560 10 mM, -20 °C 1:100 in Aq. Dest 1:1000 0,1 μM 
SNAP Substances, per 2 mg,  
-20 °C 
800 μl DMSO (prepared 
immediately before use), 
1:11.3 in the medium 
1:100 10 μM 
TNFα 10 μg/ml, 4 °C 1:10 in PBS 1:100 10 ng/ml 
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2.2.2. Determination of mediator’s release in the medium 
 
To explore the release of mediators by Kupffer cells, the liver macrophages are exposed to 
correspondent stimuli. At indicated time points supernatant is removed, centrifuged 10 min at 
16,000 × g at 4ºC and, if not assayed immediately, frozen and kept at -20ºC. 
 
 
2.2.2.1. Enzyme linked assay (PGE2 / TxB2) 
 
The amounts of PGE2 and TxB2 (stable end product TxA2) release by Kupffer cells in the 
media are determined by specific enzyme linked assay, type blocking enzyme linked assay 
(ELISA) (Fig. 2.1) (Dieter et al., 1999). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.2.1a. Preparing of Prostanoid-BSA-complexes 
 
PGE2 or TxB2 ethanol stock solution (1 mg/ml) is evaporated under N2 and 1% (w/v) aqueous 
prostanoid solution is prepared. 40 µl of this is mixed with 1.6 ml of ELISA Conjugation 
Solution form the Prostanoid-BSA-complexes followed titration by 1 M NaOH to set pH 6.0.  
The dialysis tube is boiled prior to use for 10 min in NaHCO3/EDTA-solution to remove the 
heavy metals followed washing with Aq. dist. Thereafter the dialysis of Conjugation 
complexes against 2 L of water for 3 h at RT under constant agitation is performed to remove 
uncoupled prostanoid. The final volume is adjusted to 10.4 ml by PBS (pH 7.4). 
 
 
2.2.2.1b. Immobilization of prostanoid on the plate 
 
The microtiter plates are coated using with Prostanoid-BSA-complexes (200 μl/well) diluted 
in the ELISA Buffer I in ratio 1:500. Plates are incubated at 4°C ON followed by twice 
washing by ELISA Washing Buffer (300 μl/well). The coat is blocked by ELISA Buffer II 
(300 μl/well) followed by incubation for 1 h at RT and twice washing. The plates are stored 
for 3 month at 4°C. 
 
 
 
 
 
Fig. 2.1. Blocking ELISA 
PGE2/TxB2 
1.AB 
2.AB 
Substrate 
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2.2.2.1c. Preparation of prostanoid calibration standards 
 
Prostanoid (PGE2 or TxB2) stock solution (1 μg/ml) is diluted 1:40 and 1:6.4 for PGE2 and 
TxB2 respectively with cell culture medium and next dilutions are performed 1:2.5 as 
following (Table 2.14.): 
 
 
Table 2.14. Dilutions of prostanoid stock solutions for ELISA Table 2.14. 
 
Final concentration, pg/100μl N of standard 
PGE2 TxB2 
1 2 500 15625 
2 1 000 6250 
3 400 2500 
4 160 1000 
5 64 400 
6 25.6 160 
7 10.2 64 
8 4.1 25.6 
9 1.6 10.2 
 
 
 
 
2.2.2.1d. Assay procedure 
 
Background and blank values (respective cell culture medium), all standards and supernatant 
samples are pipetted to 96-well microtiter plates in duplicate (100 µl/well). The stock solution 
of Anti-PGE2 or Anti-TxB2 antibodies (1 mg/ml) is diluted in ratio 1:100 with ELISA Buffer 
II and added (100 μl/well), except the wells for background value (ELISA Buffer II instead of 
antibodies). The plate is incubated at 4°C ON followed by twice washing with ELISA 
Washing Buffer (300 μl/well). 
Thereafter the stock solution of secondary biotin-SP-conjugated anti-mouse IgG is diluted in 
ratio 1:5 000 with ELISA Buffer II and assayed (200 μl/well). The plate is incubated for 1 h at 
RT and twice washing as described above. 
ELISA substrate’s solution is assayed (200 μl/well) and the plate is incubated at RT under 
constant shaking until the green colour appears (for 20 min – 2.5 h, in dependence of cell 
culture medium). The absorbance is measured by Dynatech Plate Reader at the wavelength of 
405 nm. Amounts of prostanoid in the supernatant are calculated using the PGE2/TxB2 
calibration curve prepared for each experiments. 
 
 
2.2.2.3. Determination of NO 
 
NO content in the cell supernatant is assayed using the Griess reaction (Green et al., 1982), 
which quantifies the nitrite content; NO is an unstable molecule and degrades to nitrite and 
nitrate. 
The calibration standards are prepared by successive dilution of NaNO2 stock solution (10 
mM) with Aq. dest. as following (Table 2.15.): 
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Table 2.15. Dilutions of nitric oxide solution for assay Table 2.15. 
 
N of NaNO2 standard 
solution Dilution ratio Final concentration 
1 1:10 1 mM 
2 1:2 500 μM 
3 1:10 100 μM  
4 1:10 50 μM 
5 1:10 10 μM 
6 1:10 5 μM 
7 1:10 1 μM 
8 Aq. dest. Blank 
 
 
Blank value, all standards and supernatant samples are pipetted to 96-well microtiter plates in 
duplicate (150 µl/well). Thereafter the components of Griess reaction are successive added 
into each well as following: 20 μl/well of 10 mM sulphanilamide solution; 10 μl/well of 1 
mM naphthalenediamine and 10 μl/well of 2 M HCl. After 10 minutes at room temperature, 
the optical density of the samples is measured using Dynatech Plate Reader at 550 nm. The 
concentration of nitrite in the samples is determined from standard curves prepared for each 
experiment  
 
 
2.2.3. Biochemical methods 
 
2.2.3.1. Cells viability assay 
 
Kupffer cells are exposed to correspondent stimuli and at indicated time points supernatant is 
removed, centrifuged 10 min at 10,000 × g and 2 × 50 μl of each samples are used for assay. 
Cells are washed twice with PBS and the cells lysate is prepared using Cell Lysis Buffer (with 
Triton), as described in Chapter 2.2.3.3. “Preparation of protein lysate”; 2 × 5 μl of each 
lysate samples are used. 
Cells viability is determined using Cytotoxicity Detection Kit (Merck) on the 96-well 
microtiter plate in accordance to the manufacture’s protocol. The absorbance of samples is 
finally measured by Dynatech Plate Reader at the wavelength of 490 nm. The ratio of LDH 
content in the cell and in the supernatant indicates about the level of cell’s death in response 
of distinct stimulation comparing to control cells. 
 
2.2.3.2. Prostanoid synthase activity in situ assay (modified after Stichtenoth et al., 2001) 
 
Primary culture of Kupffer cells is incubated in RPMI medium containing 10% NCS in the 
presence of acetylsalicylic acid (1 mM). The medium should be prepared immediately before 
use by dissolving of 0.1802 g of acetylsalicylic acid (ASA) in 10 ml of RPMI medium 
containing 10% NCS to obtain the stock ASA solution (10 mM). Thereafter ASA stock 
solution is dissolved 1:10 in the medium and the obtained medium containing ASA (final 
concentration 1 mM) replaces the old culture medium, in which cells has been kept in primary 
culture for 48 h before use. 
In experiments, required the activated macrophages, LPS (500 ng/ml) is additionally added. 
After 24 h of incubation the supernatant is removed, cells are washed twice with PBS and 
covered with 1 ml of Hanks solution containing 10 μM of PGH2 or the equal amount of 
acetone (which is solvent of PGH2 stock solution). 
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After 5 min of incubation on ice, the reaction is terminated by 50 μl of mixture containing 400 
mM FeCl2 and 4 mM of citric acid. Thereafter supernatant is removed, centrifuged for 10 min 
at 16,000 × g and the amounts of released prostanoid are determined by ELISA. 
 
 
2.2.3.3. Preparation of protein lysate 
 
2.2.3.3a. Preparation of total protein lysate 
 
At indicated time points of incubation cells are washed twice in sterile phosphate-buffered 
saline and frozen in liquid nitrogen. 
When protein lysate is prepared, cells are overlaid with 80 μl of ice-cold Cell Lysate buffer 
(for Ø 35 mm plates). After 10 min of incubation on ice, cells are scraped from the culture 
dish using rubber policeman. Protein extract is transferred in a microcentrifuge tube and 
plates are washed with 20 μl of Lysate Buffer. The flowthrough is also added to extract and 
they are passed several times through a 26-gauge needle or sonicated by ultrasonic 
homogenizer (Sonopuls) 3 time per 10 s. Cellular debris is removed by centrifugation at 
16,000 × g for 15 min at 4ºC and total cell lysate is obtained. 
When both protein extract and total RNA are prepared from the same cells, total proteins are 
obtained using Trisol LS Reagent from the organic phase after DNA removing in accordance 
as described by supplier. 
 
2.2.3.3b. Preparation of subcellular fractions (modified after Ways et al., 1992; Ambs et al., 
1995 and Stichtenoth et al., 2001) 
 
For membrane/cytosolic protein fraction preparation, the correspondent Cell Lysate Buffer 
(Triton free or sucrose Buffer) is applied to cells as described above. After cells 
homogenisation, crude cellular debris is removed by successive centrifugation at 1 000 × g for 
10 min and at 10 000 × g for 15 min at 4ºC. The half of supernatant is obtained total protein 
extract and used as control. 
The rest of supernatant is centrifuged at 350 000 × g for 30 min at 4º and supernatant is 
removed (cytosolic fraction). To obtain the microsomal fraction the pellet is twice washed in 
Cell Lysate Buffer (Triton free or sucrose Buffer) and then resuspended in the same buffer, 
using the volume equal to volume of cytosolic fraction. 
 
 
2.2.3.4. Determination of protein concentration 
 
The protein concentration is determined: 
 by modified method of Bradford (Bradford, 1976) using Bio-Rad protein detection kit 
(if the lysate is prepared using Cell Lysate Buffers); 
 by bicinchoninic acid assay after Smith et al., 1985 using BCA assay kit (Sigma) (if the 
protein extract is prepared with Trisol LS reagent and contains the high concentration of 
SDS); 
 
The determination by both Bradford and BCA methods is performed as described in the 
supplier’s protocol. The absorbance of samples is finally measured at the wavelength of 
490 and 562 nm respectively using Shimadzu Mini spectrophotometer (or Dynatech Plate 
reader, if the measurement is performed on the 96-well microtiter plate). 
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 by Amido Black staining after Dieckmann-Schuppert et al., 1997 (if the concentration is 
measured in the samples are ready to apply for SDS-PAGE ant contain loading buffer and 
ME). 
 
The determination by the Amido Black staining method is performed using 96-well microtiter 
plates. The calibration standards are firstly prepared by successive dilution of BSA stock 
solution (4 mg/ml) with Aq. dest. as following (Table 2.16.): 
 
 
Table 2.16. Dilutions of BSA solution for assay   Table 2.16. 
N of BSA standard 
solution Dilution ratio Final concentration 
1 - 4 mg/ml 
2 1:2 2 mg/ml 
3 1:2 1 mg/ml 
4 1:2 0.5 mg/ml 
5 1:2 0.25 mg/ml 
6 1:2 0.125 mg/ml 
 
 
 
Blank value, all standards and protein samples are pipetted duplicate to 96-well microtiter 
plates containing Ø 5 mm discs of cellulose acetate sheets (3 µl/discs) directly on discs. The 
discs are dried using hair-drier and subsequently immersed in the Amido Black Staining 
Solution (5 µl/discs). Staining for 10 min at RT is followed by 4 washes (250 µl/well) by 
Amido Black Assay Washing Buffer for 5 min each. The discs are dried and the Amido Black 
Assay Dissolution Buffer is added (200 µl/well). After incubation for 50 min at 50°C (or 15 
min at RT) under constant shaking the cellulose acetate sheets are dissolved yielding the 
resulting blue solution. The absorbance is measured using Dynatech Plate reader at the 
wavelength of 620 nm. 
 
 
 
2.2.3.5. SDS-PAGE (modified after Laemmli, 1970) 
 
Protein separation is performed by SDS-PAGE using small (Bio-Rad, gel 73×100 mm) and 
large (SE600, gel 160×180 mm) electrophoresis chamber. Protein samples are diluted with 5 
× loading buffer, then ME is added to final concentration 4% (v/v) and samples are heated at 
95 °C for 5 min. 
Obtained samples are loaded onto the SDS-polyacrylamide gel, prepared by successive 
polymerization of running and stacking gel solutions in the gel electrophoresis unit. The 
concentration of acrylamide in the running gel and thickness of gel are used as following: 
10%, 1,5mm thick gel –for cPLA2 (Ambs et al., 1995); 0.75 mm thick: 10% - for COX-1,-2 
and TxAS; 12% - for PGE2, PGF2α and PGD2 synthases). 
The amounts of loaded proteins are 10 and 25 μg/lane for small and large gel respectively; for 
cPLA2 investigation the double amounts of total protein are used. The both biotynilated and 
pre-stained molecular weight standards are applied to first and last wells at the amounts 0.5 – 
1 μg. 
Gels run in the Running Tris-Glycin Buffer at constant current for 10 and 17.5 mA/gel/0.75 
mm thick for small and large gel respectively until the proteins are well concentrated into the 
stacking gel. Then 20 and 35 mA/gel/0.75 mm thick respectively are applied until the tracking 
dye reaches the bottom of the gel (approximately after 1 h and 2.5 h for small and large gel 
respectively). 
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When the molecular weight of proteins is determined, the gradient SDS-PAGE is applied. The 
gradient transition of acrylamid concentration in the running gel is used usually from 4% to 
20% (w/v). The gradient running gel is poured with a model 385 Bio-Rad gradient former 
using 10 ml of each Gradient Running Gel Solutions of light and heavy density, containing 
4% and 20 % of acrylamid respectively. The samples loading and the run conditions are as 
described above. 
 
 
2.2.3.6. Western blot analysis 
 
The separated proteins are electrophoretically transferred to nitrocellulose membrane using a 
semidry transblot apparatus.  
For blotting are used 2 layers of five blotting papers and the membrane with size 50×80 and 
100×140 mm for small and large gel respectively. Both membrane and blotting paper are 
soaked in the Blotting buffer prior to use. The transfer is performed at 1 mA/cm2 for 2 h at RT 
or at 2 mA/cm2 for 1 h at 4°C. Thereafter the membrane is washed once in TBS for 5 min and, 
if necessary, is stained with Fast Green, as indicated below. 
Then membrane is blocked with 5% milk solution in TBS-T for 2 h at RT or for 1 h at 37°C 
(using orbital incubator). After five times washing with TBS-T for 5 min, the membrane is 
incubated for 2 h at RT or overnight at 4ºC with antibodies against target protein. The primary 
antibodies are diluted in TBS-T containing 5% (w/v) BSA with ratios, indicated in the Table 
“Primary antibodies”. 
Membrane is washed again five times with TBS-T for 5 min and incubated for 1 h at RT or 
for 30 min at 37°C (by means orbital incubator) with the appropriate horseradish peroxidase-
conjugated secondary antibodies diluted in TBS-T containing 5% (w/v) of milk powder 1:2 
000 and 1:10 000 for Anti-Mouse/Rabbit and Anti-Biotin antibodies respectively. Thereafter 
membrane is washed 5 times with TBS-T for 5 min. 
Immunoreactive bands are detected using ECL kit as described in the supplier’s instruction 
and exposed in the high performance chemiluminescence system “Genegnome” (Syngene); 
the image series capture is used and exposing time varies between 2-20 min. Prestained and 
biotinylated SDS-PAGE Standards serve as molecular weight standards. 
If samples contain a few amounts of target protein or the antibodies are weak, the expose X-
ray film for the same time periods is performed following by scanning of film in the through 
light scanner. 
 For quantitative analysis Western blot’s images are exported as TIFF-files into 
ImageQuaNT® software Version 5.0 (Molecular Dynamics®) and volume quantitation is 
performed by calculating the integrated intensity of all pixels inside drawn objects identified 
specific bands of Western blot. The background correction is performed using the background 
values such as object or local average.   
Membrane thereafter may be stripped and reprobed with a different antibody. After five times 
washing with TBS-T for 5 min, the membrane is incubated twice in the 60-100 ml of 
Stripping buffer at 50°C for 20 min each time with occasional agitation followed by blocking 
with 5% milk solution in TBS-T and re-probing with antibodies as described above. 
 
 
2.2.3. Protein staining 
 
If necessary, the completeness of protein blotting is visualized using Coomassie Brilliant Blue 
staining (untransferred proteins in the gel) and Fast Green Staining (transferred proteins on 
the membrane). 
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2.2.3.6a. Coomassie Blue staining 
 
The gel is stained in Coomassie Staining solution for 15 min at RT under constant agitation. 
After thoroughly washing with Aq. dest, proteins in gel are monitored. 
If necessary, gel is destained by washing twice in Coomassie Destaining solution. 
 
 
 
2.2.3.6b. Fast Green staining 
 
The membrane is overlaid by Fast Green Staining solution for 5 min at RT. The background 
staining is removed by thoroughly washing with Aq. dest, and transferred proteins on the 
membrane are examined. The membrane is scanned using PowerLook scanner. 
Thereafter membrane is destained by washing twice with 0.2 M NaOH for 10 min and final 
washing with Aq. dest. 
 
 
 
2.2.4. Methods of molecular biology 
 
2.2.4.1. Preparation of total RNA 
 
All equipment used for RNA preparation is RNase-free by treatment with 0.1% (v/v) DEPC 
solution for 24 h followed by autoclaving for 2 h. All aqueous solutions are prepared using 
RNAase-free water, which is either available commercially (contains in Quiagen’s kit) or 
prepared after treatment by DEPC as described above. 
At indicated time points of incubation cells are washed twice in sterile phosphate-buffered 
saline and frozen in liquid nitrogen. The preparation of total RNA is performed by means of 
either Quiagen RNeasy kit or Trisol LS reagent, if the proteins lysate is monitored 
simultaneously.  
When Quiagen’s product is used, the disruption and homogenization of cells is performed 
using QIAshredder spin columns. Thereafter the preparation of total RNA is performed as 
described in the RNeasy kit’s protocol including DNA digestion with RNase free DNase.  
The preparation of RNA using Trisol LS reagent is performed as described in the supplier’s 
instruction followed by protein extract preparation. 
Purified RNA are supplied with Ribonuclease inhibitor RNAsin with final concentration 1 
U/µl and the RNA content and purity are measured spectrophotometrically at 260 and 280 nm 
using NanoDrop® apparatus and software or Pharmacia Ultrospec III spectrophotometer. 
 
 
 
2.2.4.2. RNA agarose gel electrophoresis  
 
For routine check the RNA integrity and quality is used the native agarose gel electrophoresis 
with samples, denatured by urea, followed by staining with ethidium bromide.  
Diluted samples, containing 2 µl of isolated RNA (or RNA marker) and 1 × Urea Gel Loading 
Buffer, are denatured for 15 min at 75°C and immediately chilled thereafter. Samples are 
loaded in the agarose gel and resolved electrophoretically in 1 × TBE buffer at 6 V/cm, using 
horizontal agarose chamber. After the running dye is reached 2/3 of track, the gel is taken off 
and the ethidium bromide staining is visualized under UV using gel analysis system 
„GeneGenius” followed by processing with “GeneSnap” software. 
The inspection of the 28S and 18S rRNA bands estimates the integrity and overall quality of 
RNA. 
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2.2.4.3. Design of oligonucleotide primers 
 
The appropriate sequence of oligonucleotide primers for PCR analysis are either extracted 
from published works or constructed from the known cDNA sequences, using the 
 “Primer3” (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi)    and   
 “BLAST” (http://www.ncbi.nlm.nih.gov/BLAST/)    software. 
Sequences of own constructed primers are selected: 
- to have a range 17-28 of base length; 
- to content no polybase sequences; 
- to be un-comlementar to other primers used in the same PCR; 
- to yield the PCR product with length less as 1 kb; 
- to have a melting  temperature in range 55-80 °C, close to Tm of other primer, used in the 
reaction. 
The own constructed primers are monitored by sequencing of obtained PCR products. They 
are purified by High Pure PCR Product Purification Kit in accordance to the instruction 
manual. The sequencing is performed by Mrs. Glenis Wiebe (Laboratory 135, Max Planck 
Institute of Molecular Cell Biology and Genetics, Dresden, Germany). 
 
 
2.2.4.4. RT-PCR analysis 
 
Total RNA in amount of 1 μg are reverse transcribed in the Perkin Elmer PCR system 2400 
using SuperScript reverse transcriptase in 50 mM Tris-HCl (pH 8,3), 75 mM KCl, 3 mM 
MgCl2, 10 mM DTT, 0,5 mM of each dATP, dGTP, dCTP and dTTP and 25 μg/ml Oligo 
(dT)15 Primer, as described in the supllier’s instruction. 
Thereafter the polymerase chain reaction is performed using Perkin Elmer PCR system 2400. 
The PCR mixture consists of 50-200 ng of cDNA (depending on contents of target RNA in 
the cell) and master mix, containing 1 U of Taq DNA polymerase, 0,2 mM of each dATP, 
dGTP, dCTP and dTTP, 1 μM of each specific primers, 1,5 mM MgCl2, 50 mM KCl and 20 
mM Tris-HCl (pH 8.4). 
The cycling conditions for all reactions are: initial melt 95°C/135 s; annealing and extention 
95°C/45s, Tann/30s, 72°C/60s, repeated for N cycles; final extention 72°C/7 min following 
4°C, where Tann and N are indicated for each primer above. 
To compare the levels of different mRNA in the cell, β-actin is chosen to standardize the 
different samples. 
Both amplified cDNA fragments and DNA standards are resolved electrophoretically on 2% 
agarose gel and visualized by ethidium bromide, as described for RNA agarose gel.  Gel 
Loading Buffer is added either to PCR master mix before reaction (5 × Gel Loading Buffer I) 
or to ready PCR products (6 × Gel Loading Buffer II). 
For quantitative analysis gel’s images are exported as TIFF-files and processed as described 
for Western blot’s images. 
 
 
2.2.5. Statistical analysis 
 
The data resulting from each experimental group are expressed as means ± SEM. The 
significance in differences between the two distinct data groups is determined using unpaired 
Student’s t test. A P value less 0.05 is considered statistically significant. 
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3. RESULTS 
 
 
3.1. Prostanoid synthesis pathway in resident and LPS-stimulated Kupffer 
cells 
 
3.1.1. Time-course study of PGE2 and TxA2 release by rat Kupffer cells after LPS and 
dexamethasone treatment 
 
To assess the prostanoid production by KC during 24 h after stimulation with LPS (500 
ng/ml), the amounts of PGE2 and TxA2, released in the culture medium, are measured at time 
points 2, 4, 8 and 24 h after LPS stimulation.  
In resting cells, the release of prostanoids into the medium is very low (data not shown). LPS 
induces an enhanced release of PGE2 and TxA2 in liver macrophages (Fig. 3.1.A) of 0.9±0.3 
pmol/106 cells/2 h and 38±3 pmol/106 cells/24 h for PGE2 and 54±11 pmol/106 cells/2 h and 
108±16 pmol/106 cells/24 h for TxA2, respectively. 
The effect of LPS differs in release rates during the 24-hours period of incubation (Fig. 
3.1.B).  The PGE2 production has a lag phase of 2-4 h from a very low release (0.5±0.1 
pmol/106cells/h) to subsequent linear increase up to 24 h (2.2±0.1 pmol/106 cells/h). The 
effect of LPS on TxA2 production starts without a time-delay (27±6.7 pmol/106 cells/h) and 
decreases during 24 h of incubation (3.2±1.8 pmol/106 cells/h). 
The activation of AA cascade can be inhibited by dexamethasone (Masferrer et al., 1994). To 
examine the effect on LPS-activated Kupffer cells, cells are pre-treated with dexamethasone 
(1 μM) for 1 h (Table 3.1.): the glucocorticoid leads to inhibition of both PGE2 and TxA2 
release. The effect of dexamethasone appears at the same time, when the action of LPS 
becomes significant (after 4 h). 
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Fig. 3.1. Time course study of the PGE2- and TxA2-release by LPS-treated liver macrophages. Liver 
macrophages (primary culture) are incubated for the indicated times in presence of LPS (500 ng/ml). The 
amounts of PGE2 (squares) and TxA2 (circles) in cell media are determined by specific ELISA as described in 
“Material and Methods”. Values are corrected for prostanoids formed by cells in the absence of LPS. Data 
shown are means ± S.E. of at least four independent experiments.
(A) Release of PGE2 and TxA2 during 24 h of LPS-stimulation. The release of prostanoids by unstimulated 
cells is as following (in pmol/106 cells/2, 4,8 or 24 h): PGE2 - 1.3±0.6 / 1.4±0.5 / 1.6±0.6 / 1.8±0.7 after 2, 4, 8 
and 24 h, respectively; TxA2 - 17.5±5.6 / 16.4±4.9 / 19.1±5.5 / 24.9±5.1 after 2, 4, 8 and 24 h, respectively.
(B) Rates of LPS-induced PGE2 and TxA2 formation. The rate is calculated as difference in the amount of 
prostanoids formed between two time points divided by the time difference. Data shown are means ± S.E. of at 
least four independent experiments. 
 Fig. 3.1. 
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4h
8h
24h
% of inhibition
87 ± 4
93 ± 3
62 ± 10
69 ± 10
99 ± 1 86 ± 4
PGE2 TxA2
Table 3.1. Effect of dexamethasone on LPS-treated liver macrophages. Liver macrophages   (primary 
culture)  are  pretreated  for  1 h  with  dexamethasone  (+Dex; 1 µM) or solvent (-Dex). Then fresh 
medium with LPS (+LPS; 500 ng/ml) or without (-LPS) is added and macrophages are incubated for the 
indicated times. The amounts of PGE2 and TxA2 in cell media are determined by specific ELISA as 
described in “Material and Methods”. The release of prostanoids by resting cells is (in pmol/106 cells/4, 8 
and 24 h): PGE2 - 1.6±0.6 / 1.6±0.6 / 2.0±0.9 after 4, 8 and 24 h and TxA2 - 14±7 / 20±8 / 27±2 after 4, 8 
and 24 h , respectively. The release of prostanoids by LPS-activated cells are (the control values are 
subtracted, in pmol/106 cells/4, 8 and 24 h): PGE2 - 2.4±0.8 / 7.0±1.5 / 36.3±8.5 after 4, 8 and 24 h and 
TxA2 - 27±17 / 57±26 / 106±28 after 4, 8 and 24 h, respectively. The values are corrected for the PGE2
and TxA2 formed in the absence of stimuli. Data shown are means ± S.E. of at least three independent 
experiments.
Table 3.1. 
 
 
 
3.1.2. Effect of LPS and dexamethasone on the enzymes of arachidonic acid cascade 
 
To examine the role of LPS and dexamethasone on the enzymes of the AA cascade, 
correspondent mRNA (Fig. 3.2.) and proteins (Fig. 3.3.) are analyzed in resident, LPS- and/or 
dexamethasone treated cells.  
Resting Kupffer cells express certain amounts of mRNA encoding cPLA2, COX-1, mPGES-2, 
cPGES and TxAS (Fig. 3.2., B, -LPS/-Dex/24 h), the expression of mRNA encoding COX-2 
and mPGES-1 is very low (Fig. 3.2., A, -LPS/-Dex/0,4,8,24 h).  
LPS strongly upregulates mRNA encoding COX-2 and mPGES-1 (Fig. 3.2., A, +LPS/-Dex/4, 
8, 24 h). Densitometric data for the mRNA analysis are shown in Fig. 3.5.A and Fig. 3.7.A, 
respectively. LPS upregulates the expression of mRNA encoding cPLA2 and mPGES-2 but 
does not alter mRNA encoding COX-1, cPGES, TxAS (Fig. 3.2., B, +LPS/-Dex/24 h). 
Dexamethasone downregulates the LPS-enhanced expression of mRNA encoding COX-2 and 
mPGES-1 (Fig. 3.2., A, +LPS/+Dex/4, 8, 24 h). In resting and LPS-activated cells 
dexamethasone downregulates weakly the expression of mRNA encoding cPLA2 and 
mPGES-2 but does not affect the expression of mRNA encoding COX-1, cPGES, TxAS (Fig. 
3.2., B, -LPS/+Dex/24 h and +LPS/+Dex/24 h). 
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Fig. 3.2. Regulation of mRNA’s transcript encoding COX-2 and mPGES-1 (A), cPLA2, COX-1,  mPGES-
2, cPGES and TxAS (B) by LPS and dexamethasone in liver macrophages. Liver macrophages   (primary 
culture)  are  pretreated  for  1 h  with  dexamethasone  (+Dex; 1 µM) or solvent (-Dex). Then fresh medium 
with LPS (+LPS; 500 ng/ml) or without (-LPS) is added and macrophages are incubated for the indicated 
times. The expression of indicated enzymes is analyzed as described in “Material and Methods”. A 
representative set of three independent experiments is shown. The data of densitometric analysis for mRNA 
encoding COX-2 and mPGES-1 is shown in Fig. 3.5.A and Fig. 3.8.A, respectively; the expression of other 
enzymes in LPS-activated cells is as following (24 h, -Dex/-LPS corresponds 100; data are means ± S.E.): 
cPLA2 135±9; COX-1 104±9; mPGES-2 150±25; cPGES 98±12; TxAS 95±1.
cPLA2 309 bp
Fig. 3.2. 
 
 
 
Similar results are obtained by Western blot analysis; COX-1, mPGES-2, cPGES and TxAS 
proteins are expressed by resting Kupffer cells (Fig. 3.3., B, -LPS/-Dex/24 h). In contrast, the 
synthesis of cPLA2, COX-2 and mPGES-1 proteins is very low in the absence of stimuli (Fig. 
3.3., A, -LPS/-Dex/0, 4, 8, 24 h).  
The expression of cPLA2, COX-2 and mPGES-1 protein is enhanced when LPS is added (Fig. 
3.3., A, +LPS/-Dex/4,8,24 h). In contrast, COX-1, mPGES-2, cPGES and TxAS protein 
expression is not changed by LPS (Fig. 3.3., B, +LPS/-Dex/24 h). 
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Dexamethasone suppresses the LPS-enhanced expression of COX-2, mPGES-1 and cPLA2 
proteins (Fig. 3.3., A, +LPS/+Dex/4, 8, 24 h). Dexamethasone does not affect the expression 
of COX-1, cPGES, mPGES-2, TxAS protein in resting and LPS-activated cells (Fig. 3.2., B, -
LPS/+Dex/24 h and +LPS/+Dex/24 h).  
 
 
 
A
B
mPGES-1
4 h0 h 8 h 24 h
Dex
LPS +
+ +
+ +
+ +
+
COX-2
16 kDa
72 kDa
TxAS
COX-1 70 kDa
60 kDa
cPGES 23 kDa
Dex
LPS +
+ +
+
24h
33 kDamPGES-2
cPLA2 110 kDa
Fig. 3.3. LPS and dexamethasone regulate the synthesis of cPLA2, COX-2 and mPGES-1 (A), but do not 
regulate the synthesis of COX-1, mPGES-2, cPGES, TxAS (B) in liver macrophages. Liver macrophages   
(primary culture)  are  pretreated  for  1 h  with  dexamethasone  (+Dex; 1 µM) or solvent (-Dex). Then fresh 
medium with LPS (+LPS; 500 ng/ml) or without (-LPS) is added and macrophages are incubated for the 
indicated times. The synthesis of indicated enzymes is analyzed as described in “Material and Methods”. A 
representative set of three independent experiments is shown. The data of densitometric analysis for COX-2 and 
mPGES-1 are shown in the Fig. 3.5.B and Fig. 3.8.B, respectively; the synthesis of other enzymes in LPS-
activated cells is as following (24 h, -Dex/-LPS corresponds 100; data are means ± S.E.):  cPLA2 109±15 / 
193±15 / 220±39 for 4/8/24 h of incubation; COX-1 95±5; mPGES-2 95±5; cPGES 106±5; TxAS 90±11.
+
+ +
+
Fig. 3.3. 
 
 
III. Results                                                                56 
   
3.1.2.1.Regulation of cytosolic phospholipase A2 
 
Cytosolic PLA2 Group IV is the key enzyme, which releases arachidonic acid from 
phospholipids. cPLA2 is expressed at a low level in resident liver macrophages (Fig. 3.2.- Fig. 
3.4.). Thus, the enzyme can be rapidly (during 10 min) activated by agents (Dieter et al., 
2002). 
LPS upregulates cPLA2 mRNA expression (Fig. 3.2.B), resulting in 135%±9% of basal 
cPLA2 expression. 
The level of cPLA2 protein expression (Fig. 3.3.) is about 3 fold enhanced compared by 
control cells (304%±58% vs. control cells) after 24 h of incubation with LPS. LPS also 
induces a phosphorylation of cPLA2 (Fig. 3.4.).  
Dexamethasone suppresses the LPS-induced expression and phosphorylation of cPLA2 by 
49%±6% and 72%±13%, respectively (Fig. 3.4.). 
 
 
 
 
 
 
 
Fig. 3.4. cPLA2 expression and phosphorylation in resident and LPS- and dexamethasone-treated KC. 
Liver macrophages   (primary culture)  are  pretreated  for  1 h with  dexamethasone  (+Dex; 1 µM) or solvent (-
Dex). Then fresh medium with (+LPS; 500 ng/ml) or without (-LPS) is added and macrophages are incubated 
for the indicated times. The synthesis of indicated enzymes is analyzed as described in “Material and Methods”.
A representative set of three independent experiments is shown. The synthesis of cPLA2 is (24 h, -Dex/-LPS 
corresponds 100, data are means ± S.E): 304±58 (in +LPS-activated cells), 147±28 (in +Dex/+LPS-activated 
cells). 
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Fig. 3.4. 
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3.1.2.2. Regulation of COX-1 and COX-2 
 
Free arachidonic acid is further metabolized by cyclooxygenase isoenzymes (Smith et al., 
2000). Two isoforms of COX were identified in rat Kupffer cells recently (Dieter et al., 
2000).  
The analysis of COX mRNA shows that resident liver macrophages express mRNA encoding 
COX-1, which is not significantly affected by LPS (Fig. 3.2.B, 104%±9% vs. control cells). 
Also, the expression of COX-1 protein is not influenced by LPS stimulation (Fig. 3.3.B, 
95%±5% vs. control cells). 
In contrast, other isoenzyme COX-2, is expressed at very little amounts in resident Kupffer 
cells but is strongly upregulated by LPS.  
The mRNA upregulation appears already 4 h after LPS treatment and leads to a 2,5 fold 
higher mRNA expression during the next 20 h of incubation (Fig. 3.5.A). Addition of LPS 
induces also a linear increase of COX-2 protein amounts during 24 h (Fig. 3.5.B). 
Dexamethasone completely abrogates the LPS effect after 4, 8 and 24 h on both, mRNA 
(95%±3% is inhibited) and protein level (99%±1% is inhibited). 
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Fig. 3.5. Time-course study of COX-2: its expression (A) and synthesis (B) in LPS- and dexamethasone-
treated cells. Liver macrophages are executed as described in Fig. 3.2., Fig.3.3. The quantitative analysis of 
mRNA (A) and proteins (B) of COX-2 is performed as described in “Materials and Methods”. The values of 
specific bands are standardized using actin as internal standard. 24 h, -Dex/-LPS corresponds 100%. Data 
shown are means ± S.E. of three independent experiments.
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Fig. 3.5. 
3.1.2.3. Regulation of the final prostaglandin E2 synthase 
 
Recently, three final PGE2 synthases have been described (Jakobsson et al., 1999b; Tanioka et 
al., 2000; Tanikawa et al., 2002). To identify which enzymes are expressed in Kupffer cells, 
the analysis of mRNA encoding final PGE2 synthases and Western blot analysis are 
performed. The data show that Kupffer cells express three final PGE2-synthase isoenzymes: 
microsomal mPGES-1 and mPGES-2, and cytosolic PGES. 
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Fig. 3.6. Expression of mPGES-1, mPGES-2 and cPGES mRNA in rat liver macrophages. Macrophages 
(primary culture) are incubated for 24 h in presence of LPS (500 ng/ml). The expression of indicated enzymes is 
analyzed as described in “Material and Methods”. A representative set of three independent experiments is 
shown. M = DNA-marker.
M
Fig. 3.6. 
 
 
 
Resident and LPS-activated KC show the different expression of mRNA encoding three 
PGE2-synthases (Fig. 3.2.A, Fig. 3.6.). The obtained PCR-products are 292, 226 and 240 bp 
of size for mPGES-1, mPGES-2 and cPGES respectively (Fig. 3.6.). 
Resident cells express very low amounts of mRNA encoding mPGES-1 but substantial 
amounts of mRNA encoding mPGES-2 and cPGES. mPGES-1 is strongly upregulated by 
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LPS treatment (1175%±200% vs. control cells), whereas mPGES-2 shows a small increase of 
mRNA expression (150%±23% vs. control cells) and cPGES expression is not changed 
(98%±12% vs. control cells). 
The kinetic of mPGES-1 mRNA expression after LPS (Fig. 3.7.A) differs from the kinetic for 
of COX-2 (Fig. 3.5.A):  while COX-2 expression is maximal already at 4 h, the PGES-1 
expression increases up to 24 h. Also, the effect of dexamethasone on mPGES-1 is different: 
during the first 8 h, dexamethasone inhibits the expression only by 21%±8%, after 24 h the 
inhibition is 83%±9%. 
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Fig. 3.7. Time-course study of mPGES-1: its expression (A) and synthesis (B) in LPS- and 
dexamethasone-treated cells. Liver macrophages are executed as described in Fig. 3.2., Fig.3.3. The 
quantitative analysis of mRNA (A) and proteins (B) of mPGES-1 is performed as described in “Materials and 
Methods”. The values of specific bands are standardized using actin as internal standard. 24 h, -Dex/-LPS 
corresponds 100%. Data shown are means ± S.E. of three independent experiments.
Fig. 3.7. 
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3.1.2.4. Localization of the final PGE2-synthases 
 
For subcellular distribution, Western blot analysis is performed with cell lysates and with both 
microsomal and cytosolic fractions (Fig. 3.8.).  
mPGES-1 (after LPS stimulation) is found  almost totally in the microsomal fraction 
(98%±2% vs. total cell lysate, Fig. 3.8.A). mPGES-2 (control and after LPS stimulation) is 
found by 75%±2% in the microsomal fraction (Fig. 3.8.B). cPGES (control and after LPS 
stimulation) is almost completely found in the cytosolic fraction (Fig. 3.8.C) . 
 
 
 
 
Fig. 3.8. Analysis of the subcellular distribution of mPGES–1 (A), mPGES-2 (B) and cPGES (C) in 
resident and LPS-treated KC. Cells are treated for 24 h with LPS (+LPS, 500 ng/ml) or vehicle (control). 
Cells lysate and subcellular fractions are analyzed as described in “Materials and Methods”. A representative set 
of three independent experiments is shown. L = total cell lysate, C = cytosolic fraction, M = microsomal 
fraction.
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3.1.2.5. TxA2 synthase cellular activity (in situ) 
 
TxA2-synthase activity is measured in control and LPS-treated cells (Fig. 3.9.). LPS-
stimulated and control cells are kept with acetylsalicylic acid in order to block the production 
of PGH2 by COX isoenzymes. Thereafter, PGH2 is added exogenously.  
Fig. 3.9. shows that the release of TxA2 in both activated and control cells after PGH2 is about 
the same (96%±8% vs. control cells). 
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Fig. 3.9. The activity of TxA2-synthase in resident and LPS-activated KC. Liver macrophages (primary 
culture) are incubated for 24 h in presence (+LPS) or absence (C) of LPS (500 ng/ml) in the medium containing 
acetylsalicylic acid (1 mM). TxA2-syntase activity assay is performed and the amounts of TxA2 are measured as 
described in “Material and Methods”. The means ± S.E. of at least four independent experiments are shown. The 
release of TxA2 by PGH2-treatment resident cells is 186±51 pmol/106 cells (corresponds 100%). #P>0.05 vs. 
control cells.
C + LPS
+ PGH2 +vehicle medium
(no cells)
R
at
e 
of
 T
xA
2
re
le
as
e,
 %
#
C + LPS + PGH2 + vehicle
Fig. 3.9. 
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3.1.2.6. Localization of enzymes of the AA cascade  
 
cPLA2, COX-1, COX-2 and cPGES-1, mPGES-1, mPGES-2 and TxA2-synthase show a 
different distribution between the cytosolic and membrane fraction in LPS-treated 
macrophages after 24 h of incubation (Fig. 3.10.). In detail, cPLA2 and mPGES-1 are 
localized only in the membrane fraction; COX-1, COX-2, mPGES-2 and TxAS are found to 
80% in the membrane fraction and to 20% in the cytosolic fraction. cPGES is localized 
mainly in cytosol (92%). 
The mentioned membrane enzymes are able to shift to the subcellular fractionation in the 
presence of Triton-X, solubilising the association to cellular membrane (data not shown). 
 
 
 
 
 
Fig. 3.10. Localization of enzymes in LPS-activated Kupffer cells. Cells (primary culture) are incubated for 
24 h in presence of LPS (500 ng/ml). Subcellular fractions are executed and the synthesis of indicated enzymes 
is analyzed as described in “Materials and Methods”. A representative  set  of three  independent experiments 
is shown. The data of densitometric analysis are (cyt : mem, %): cPLA2 0:100; COX-1 20:80; COX-2 10:90; 
mPGES-1 0:100; mPGES-2 25:75; cPGES 92:8; TxAS 20:80. C = cytosolic fraction, M = microsomal fraction
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Fig. 3.10. 
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3.1.3. Inhibition of LPS-induced PGE2 and TxA2 release by specific COXs inhibitors 
 
To estimate the role of COX-1 and COX-2 in prostanoid production specific COX-1 and 
COX-2 inhibitors (Dieter et al., 2000) SC560 and SC236 are used (Table 3.2.). The effect of 
inhibitors is measured after 8 h and 24 h of KC incubation. The inhibition of PGE2 at earlier 
time points could not be determined because of the very low PGE2 release. 
The COX-1 inhibitor SC560 suppresses the PGE2- and TxA2-release after LPS at 8 h and 24 h 
(Table 3.2.A). The COX-2 inhibitor SC236 shows a different effect: at 8 h the PGE2- and 
TxA2-release is inhibited by 77% and 20% respectively; after 24 h, PGE2–release is decreased 
to 42%, whereas TxA2-release is increased to 34%.  
The COX-non-specific inhibitor indomethacin inhibits both PGE2 and TxA2 release almost 
completely (Table 3.2.B).  
 
 
Table 3.2. Effect of COX inhibitors on the LPS-induced release of PGE2 and TxA2 by liver macrophages. 
(A) Effect of specific inhibitors of COX-1 (SC560) and COX-2 (SC236) on the LPS- induced release of 
PGE2 and TxA2 from liver macrophages. Liver macrophages   (primary culture)  are  pretreated  for  1 h with 
without/with 0,1 µM SC560 or 1 µM SC236. Then fresh medium with LPS (500 ng/ml) is added and 
macrophages are incubated for the indicated times. The amounts of PGE2 and TxA2 are determined by specific 
ELISA as described in “Material and Methods”. Data shown are means ± S.E. of at least three independent 
experiments. The release of prostanoids without inhibitors in LPS-pretreated cells after 8h / 24h is 19±2/64±6 
and 49±6/53±2 pmol/106 cells/8 or 24 h, respectively. * P<0,001,  ** P <0,01 (COX-1 inhibition vs. COX-2 
inhibition). 
(B) Suppression of prostanoid synthesis by indomethacin. Liver macrophages   (primary culture)  are  
pretreated  for  1 h  with without/with indomethacin (1 µM). Then fresh medium with LPS (500 ng/ml) is added 
and macrophages are incubated for 24 h, the amounts of PGE2 and TxA2 are determined. Data shown are means 
± S.E of at least five independent experiments. The release of prostanoids without inhibitors in LPS-treated cells 
after 24 h is 20±1 and 37±4 pmol/106 cells/24 h.
8h 24h
SC-560 
SC-236
8h 24h
SC-560 
SC-236 
% of inhibition
PGE2
TxA2
91,0 ± 1,9**
76.8 ± 4.1
95.5 ± 1.5**
42.0 ± 10.5
85.5 ± 6.0*
20.0 ± 7.9
91.6 ± 2.2*
34.3 ± 3.6
A B % of inhibition
indomethacin/LPS, 24 h
94.1 ± 3.3
85.4 ± 4.4TxA2
PGE2
Table 3.2. 
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3.2. Effects of cytokines on resident and LPS-activated KC 
 
3.2.1. Effect of IL-1β on prostanoid release 
 
Recombinant rat IL-1β induces an enhanced release of PGE2 and TxA2 in liver KC (Fig. 
3.11.).  
 
Fig. 3.11. Release of PGE2 (A) and TxA2 (B) after IL-1ß treatment. Liver macrophages (primary culture) are 
incubated for 24 h in presence (+IL-1ß) or absence (C) of IL-1ß (5 ng/ml). The amounts of PGE2 (A) and TxA2
(B) are determined by specific ELISA as described in “Material and Methods”. Data shown are means ± S.E. of 
at least three independent experiments. *P<0.005 vs control, **P<0.05 vs. control (C).
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Fig. 3.11. 
 
 
 3.2.2. Effect of TNFa on prostanoid release 
 
Recombinant rat TNFα induces a PGE2 and TxA2 release in liver KC   (Fig. 3.12.). 
Fig. 3.12. Release of PGE2 (A) and TxA2 (B) after TNFa treatment. Liver macrophages (primary culture) are 
incubated for 24 h in presence (+TNFa) or absence (C) of TNFa (10 ng/ml). The amounts of PGE2 (A) and TxA2
(B) are determined by specific ELISA as described in “Material and Methods”. Data shown are means ± S.E. of 
at least three independent experiments. *P<0.01 vs. control, **P<0.05 vs. control (C).
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3.2.3. Synergistic effect of IL-1β  and TNFa on prostanoid release by resident KC 
 
The study of cytokine action on the macrophages cannot be profound, if it does not consider 
the presence of other biologically active agents. For example, during liver injury a number of 
inflammatory cytokines is co-produced (Gross et al., 1983). The cytokine network is more 
important in case of IL-1β and TNFα, because a synergism between these cytokines has been 
reported (Dayer, 2002; Romero et al., 1996).  
To explore a possible synergistic effect of IL-1β and TNFα on PGE2 and TXA2 release by KC 
(Fig. 3.13.), cells are treated simultaneously by both cytokines. After 24 h of incubation the 
released amounts of PGE2 are by 15% and 40% higher compared to TNFα and IL-1β alone, 
respectively (Fig. 3.13.A).  
In case of TxA2, a synergistic effect is observed for IL-1β (~35% higher compared to IL-1β 
alone), but not for TNFα (Fig. 3.13.B). 
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Fig. 3.13. Synergistic effect of IL-1ß and TNFa on PGE2 (A) and TxA2 (B) release. Liver macrophages are 
kept for 24 h in the medium containing rat IL-1ß (5 ng/ml) or/and rat TNFa (10 ng/ml). The amounts of PGE2
(A) and TxA2 (B) are determined by specific ELISA as described in “Material and Methods”. The release of 
PGE2 in +IL-1ß/+TNFa-activated cells is 9.9±2.8 pmol/106 cells/24 h (corresponds 100% of PGE2 release), 
TxA2 - 27.0±8.7 pmol/106 cells/24 h (corresponds 100% of TxA2 release). Data shown are means ± S.E. of at 
least three independent experiments. *P<0.001 / **P<0.01 / ***P<0.05 vs. +IL-1ß/+TNFa-activated cells.
Fig. 3.13. 
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3.2.4. Effect of cytokines on inducible enzymes of the AA cascade in Kupffer cells 
 
To determine whether the effect of IL-1β and TNFα occurs via changes at the 
transcriptional/translational level of enzymes, the analysis of mRNA and protein expression 
of enzymes of AA cascade is performed (Fig. 3.14.).  
IL-1β and TNFα upregulate differently the mRNA expression encoding inducible enzymes 
involved in PGE2 and TxA2 production (Fig. 3.14.A). In detail, the cytokines induce a weak 
induction of cPLA2 mRNA expression (up to ~150-170% vs. control cells). The expression of 
mRNA encoding COX-2 is enhanced differently: by IL-1β up to ~280%, by TNFα up to 
~450% and by both cytokines up to ~560% compared to control cells.  
The expression of mRNA encoding mPGES-1 is almost not affected by IL-1β (~107% vs. 
control cells), but it is ~2.5 times higher when cells are treated by TNFα or TNFα+IL-1β. 
The expression of mPGES-2 mRNA is slightly induced by all stimuli, giving ~120% of 
mRNA level compared with control cells. 
The synthesis of  cPLA2, COX-2 and mPGES-1 proteins is also upregulated by cytokines; 
mPGES-2, in turn, is not altered by cytokines as well as by LPS. 
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Fig. 3.14. Effect of IL-1ß and TNFa on the expression of enzymes. Liver macrophages are incubated for 24 
h in the medium containing rat IL-1ß (5 ng/ml) or/and rat TNFa (10 ng/ml) as well as LPS (500 ng/ml), and in 
the stimuli-free medium (C). The expression of indicated enzymes is analyzed as described in “Material and 
Methods”. A representative set of three independent experiments is shown (A). The rates of enzyme’s induction 
after IL-1ß/TNFa co-incubation for mRNA encoding cPLA2, COX-2, mPGES-1,-2 is shown (B). 100% 
corresponds the expression of enzymes in control cells (C); *n=2.
B 
0%
200%
400%
600%
IL-1ß TNFa IL-1ß
TNFa
cPLA2
COX-2
mPGES-1
mPGES-2
En
zy
m
es
 tr
an
sc
rip
tio
n,
 %
**
Fig. 3.14. 
 
III. Results                                                                68 
   
3.2.5 Effect of anti-fibrogenic cytokine on prostanoid release by KC 
 
3.2.5.1 Effect of IL-6 on prostanoid production by resident KC 
 
To examine, whether IL-6 has an influence on the PGE2 release by liver macrophages, cells 
are pre-treated with recombinant rat IL-6 (to final concentration 100 ng/ml) (Fennekohl et al., 
2000) (Fig. 3.15.).  
IL-6 has no significant effect on PGE2 release in control cell or cells treated with LPS, IL-1β 
and TNFα. 
 
 
 
 
 
Fig. 3.15. Effect of IL-6 on PGE2 release by LPS- and cytokines-activated Kupffer cells. Liver macrophages 
(primary culture) are pretreated for 1 h with IL-6 (100 ng/ml) or vehicle. Then fresh medium with LPS (500 
ng/ml), rat IL-1ß (5 ng/ml), rat TNFa (10 ng/ml) and stimuli-free medium is added and macrophages are 
incubated for the next 24 h. The amounts of PGE2 in cell media are determined by specific ELISA as described 
in “Material and Methods”. Data shown are means ± S.E of three independent experiments. 100% corresponds 
the release of PGE2 in absence of IL-6 (in pmol/106 cells/24 h): 2.5±0.5 in untreated cells (C); 8.9±1.1 in LPS-
treated, 8.2±0.7 in IL-1ß-treated, 9.7±2.5 in TNFa-treated and 14.4±0.6 in combined (IL-1ß+TNFa)-treated 
Kupffer cells. P>0.05 vs. IL-6-untreated cells for all stimuli.
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3.2.5.2 Effect of IL-10 on prostanoid production by LPS-activated KC 
 
IL-10 does not effect LPS-induced PGE2 and TxA2 release after 8 h, but suppresses the 
release of PGE2 and TxA2 after 24 h by ~70% and ~50%, respectively (Fig. 3.16.). 
IL-10 also decreases the expression of enzymes (Fig. 3.17.): the expression of mRNA 
encoding cPLA2, COX-2 and mPGES-1 is downregulated to 77%±6%, 33%±8% and 
60%±7%, respectively, compared to LPS-activated cells.  
 
0%
50%
100%
Pr
os
ta
no
id
 r
el
ea
se
, %
 
8 h 24 h
PGE2
TxA2
#
##
######
Fig. 3.16. IL-10 suppresses the release of PGE2 and TxA2 by LPS-activated Kupffer cells after 24 h of 
incubation. Liver macrophages (primary culture) are pretreated for 1 h with IL-10 (10 ng/ml) or vehicle. Then 
fresh medium with/without LPS (500 ng/ml) is added and macrophages are incubated for the next 24 h. The 
amounts of PGE2 and TxA2 in cell media are determined by specific ELISA as described in “Material and 
Methods”. Data shown are means ± S.E. of at least four independent experiments. #P<0.001 vs LPS, ##P<0.005 
vs LPS, ###P>0.05, not significant. The release of prostanoids in LPS-treated cells corresponds 100% and is 
measured as following (in pmol/106 cells/8 or 24 h): PGE2 - 18.6±6.6 and 36.7±11.2 after 8 h and 24 h, 
respectively; TxA2 – 49.7±14.5 and 79.4±18.7 after 8 h and 24 h, respectively. The release of prostanoids in 
control and IL-10-treated cells is as following (in pmol/106 cells/8 or 24 h): PGE2 - 4.4±0.8 and 6.6±3.4 after 8 
h, respectively; 4.5±1.4 and 3.5±1.3 after 24 h, respectively; TxA2 – 12.3±8.4 and 6.7±3.8 after 8 h, respectively; 
16.1±7.8 and 15.8±5.1 after 24 h, respectively.
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Fig. 3.16. 
Fig. 3.17. Effect of IL-10 on expression of mRNA encoding cPLA2, COX-2 and mPGES-1 in LPS-treated 
macrophages. Liver macrophages (primary culture) are pretreated for 1 h with IL-10 (10 ng/ml) or vehicle. Then 
fresh medium with/without LPS (500 ng/ml) is added and macrophages are incubated for the next 24 h. The 
expression of indicated enzymes is analyzed as described in “Material and Methods”. A representative  set of 
three experiments  is shown. The  expression of cPLA2,  COX-2 and mPGES-1 by IL-10/LPS-treated cells are 
77±6,  33±8 and 60±7, respectively (24 h, +LPS corresponds 100). C=unstimulated cells
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Fig. 3.17. 
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3.3. Effect of PGE2 on the release of other prostanoid and cytokines 
 
 
Exogenously added PGE2 reduces TxA2 release after LPS (Fig. 3.18.A), but potentiates the 
TxA2 release by IL-1β and TNFα (Fig. 3.18.B). 
 
 
 
Fig. 3.18. Effect of PGE2 on the release of TxA2 by resident, LPS- (A) and cytokines- (B) activated KC. 
Liver macrophages are pre-incubated with PGE2 (1 µM) during 1 h. Thereafter fresh medium with LPS (500 
ng/ml), rat IL-1ß (5 ng/ml) or/and rat TNFa (10 ng/ml) is added and macrophages are incubated for 24 h. The
amounts of TxA2 in the medium are determined by specific ELISA as described in “Material and Methods”. 
Data shown are means ± S.E. of at least three independent experiments. 
(A) The release of  TxA2 in PGE2-free, in resting and PGE2-treated cells is 55.3±7.9 pmol/106 cells/24 h 
(corresponds 100%), 15±6 and 18±3 pmol/106 cells/24 h, respectively. #P<0.05 vs LPS. (B) The release of TxA2
by PGE2-free cells correspond 100% and is equal to 26.4±13.0 and 49.9±12.0 pmol/106 cells/24 h after 
incubation with IL-1ß and TNFa, respectively. *P<0.01 and **P<0.05 vs. cytokines.
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Fig. 3.18. 
 
 
In LPS-treated cells PGE2 inhibits the LPS-induced mRNA expression of cPLA2 (20%), 
COX-2 (30%) and mPGES-1 (50%) (Fig. 3.19.A) and proteins of cPLA2 (50%), COX-2 
(30%) and mPGES-1 (70%) (Fig. 3.19.B). 
PGE2 upregulates the expression of mRNA (Fig. 3.19.C) and proteins (Fig. 3.19.D) of  IL-1β- 
and  TNFα-induced enzymes. 
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Fig. 3.19. Effect of PGE2 on enzymes in LPS- and cytokines-activated KC. Liver macrophages are kept as 
described in Fig. 3.18. mRNA (A, C) and proteins (B, D) are analyzed as described in “Materials and 
Methods”. A representative set of three (A, C) and at least two (C, D) independent experiments is shown. 
(A, B) The following data are obtained after PGE2-treatment for 24 h (no stimuli, 24 h corresponds 100): 
mRNA (A) cPLA2 63±31; COX-2 53±13; mPGES-1 85±25 and proteins (B) cPLA2 13±7; COX-2 70±17; 
mPGES-1 85±25; after PGE2/LPS-treatment for 24 h (+LPS, 24 h corresponds 100): mRNA (A) cPLA2 81±6; 
COX-2 67±17; mPGES-1 47±7 and proteins (B) cPLA2 52±17; COX-2 66±9; mPGES-1 33±8. 
(C, D) The following data are obtained for PGE2/cytokines-treated cells (24 h, +IL-1ß or TNFa, respectively, 
corresponds 100): mRNA (C) cPLA2 100±0 and 147±11; COX-2 480±340 and 877±736; mPGES-1 185±37 
and 450±166 after PGE2 and IL-1ß/TNFa, respectively; proteins (D) cPLA2 155±32 and 181±1; COX-2 
376±240 and 292±51; mPGES-1 469±72 and 730±50 after PGE2 and IL-1ß/TNFa, respectively.
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3.4. Synthesis of nitric oxide in Kupffer cells 
 
3.4.1. Stimulation of NO release by LPS and cytokines 
 
LPS stimulates NO release in KC (Fig. 3.20.A). The stimulation of NO release becomes 
visible after 2-4 h and increases linearly during the next 20 h. Moreover, the rate of NO 
release after LPS treatment reaches its peak already after 8 h (4.5±0.83 mol/106 cells/h) and 
remains on this level or even slightly decreases from 8 h to 24 h (4.2±1.1 pmol/106 cells/h).  
The release of nitric oxide by LPS-activated macrophages is suppressed by dexamethasone 
(Fig. 3.20.C).  
Cytokines are also able to modulate nitric oxide release (Fig. 3.21.). When IL-1β or TNFα are 
added to resident Kupffer cells (Fig. 3.21.A), a small increase of NO release is observed after 
24 h of incubation (~7-8 nmol/106 cells, that is equal ~130%-160% vs. control cells). The 
combined action of both cytokines does not show a significant effect on NO release, giving 
~9 nmol/106 cells (that is equal ~170%-190% vs. control cells). 
 
Interleukine-10 abrogates the LPS-induced production of NO (Fig. 3.21.B). It suppresses NO 
release after 8 h of incubation down by 30%, after 24 h by 70%.  
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Fig 3.20. Time course study of NO-release by LPS- and dexamethasone-treated liver macrophages. (A)
Release of nitric oxide during 24 h of LPS-stimulation. Liver macrophages (primary culture) are incubated 
for the indicated times in presence of LPS (500 ng/ml). The amounts of NO are determined by Griess assay as 
described in “Material and Methods”. Values are corrected for NO formed by cells in the absence of LPS. Data 
shown are means ± S.E. of five independent experiments. The release of nitric oxide by resting cells is as 
following (in nmol/106 cells/4,8 or 24 h): 2.1±0.2/3.5±1.1/3.6±0.9 after 4, 8 and 24 h, respectively. (B) Rates of 
LPS-induced nitric oxide secretion. The rate is calculated as difference in the amount of NO formed between 
two time points divided by the time difference. Data shown are means ± S.E. of five independent experiments.
*P <0.001, **P <0,01 (current time point vs 8 h); &P <0.05 (current time point vs. 24 h),NSP>0.05 (current time 
point vs. 24 h). 
(C) Effect of dexamethasone on LPS-treated liver macrophages. Liver macrophages   (primary culture)  are  
pretreated  for  1 h  with  dexamethasone  (1 µM) or solvent. Then fresh medium with/without LPS (500 ng/ml) 
is added and macrophages are incubated for the indicated times. The release of NO is measured. Amounts of 
nitric oxide formed by resting cells are (in nmol/106 cells/4,8 and 24 h): 2.6±0.6/2.4±0.6/3.7±0.9 after 4, 8 and 
24 h, respectively. Data shown are means ± S.E. of at least four independent experiments.
C
0%
20%
40%
60%
80%
100%
In
hi
bi
tio
n 
of
 N
O
re
le
as
e,
 %
8 h 24 h4 h
Time, h
+Dex/+LPS
Fig. 3.20. 
III. Results                                                                74 
   
 
0
2
4
6
8
10
Fig. 3.21. Effect of cytokines on NO release. (A) Effect of IL-1ß and TNFa on the nitric oxide production 
by resident Kupffer cells. Liver macrophages are incubated for 24 h with vehicle (C), LPS (500 ng/ml), rat IL-
1ß (1 ng/ml) or/and with rat TNFa (10 ng/ml, respectively. The amounts of nitric oxide in the medium are 
determined by Griess assay as described in “Material and Methods”. Data shown are  means ± S.E. of  at  least 
three  independent  experiments.   ***P<0,05  vs. control cells.   (B) Effect of  IL-10 on the nitric oxide 
production by LPS-activated Kupffer cells. Liver macrophages (primary culture) are pretreated for 1 h with 
IL-10 (10 ng/ml) or vehicle. Then fresh medium with/without LPS (500 ng/ml) is added and macrophages are 
incubated for the indicated times. The amounts of nitric oxide in the medium are measured. Amounts of nitric 
oxide formed by IL-10-free cells are (in nmol/106 cells/24 h): 15.0±3.4 and 53.5±13.0 after 8 h and 24 h, 
respectively. Data shown are means ± S.E. of at least three independent experiments. #P<0.001 vs. LPS, 
##P<0.05 vs. LPS
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3.4.2. Nitric oxide synthase isoenzymes 
 
 
Three enzymes are known to be responsible for nitric oxide production: inducible (iNOS), 
endothelial (eNOS) and neuronal (nNOS) NO synthases (Muriel, 2000). To examine which of 
these enzymes are involved in NO release in KC, RT-PCR analysis of mRNA encoding NOS 
is performed (Fig. 3.22.A).  
 
Control and LPS-treated Kupffer cells are examined. Rat liver endothelial cells and rat brain 
are used for positive control as sources of eNOS and nNOS respectively because of their 
property to synthesize the indicated enzymes (Alderton et al., 2001).  
The RT-PCR analysis of samples demonstrates that control cells do not express significant 
mRNA amounts encoding NO synthases. LPS induces only the expression of the iNOS 
mRNA (Fig. 3.22.A, B).  
LPS also induces an expression of iNOS protein (Fig. 3.22.C).  
The upregulation of iNOS by pro-fibrogenic cytokines (IL-1β and TNFα) is much weaker 
compared to LPS-treated cells (Fig. 3.22. B,C). 
The downregulation of the enhanced both transcription and translation of iNOS is also 
studied. It is demonstrates in Fig. 3.22.D, that the expression of mRNA encoding iNOS is 
strongly suppressed by both anti-inflammatory agents: dexamethasone abrogates 99% of the 
induced iNOS transcription and after the pre-treatment of cells by IL-10, only ~1/5 of mRNA 
remains to be express.  
Despite of the previously shown relatively high (~30%) release of nitric oxide after IL-10 
treatment during 24 h of incubation, the Western blot analysis of proteins from the same 
sample displays only traces of iNOS in the cells lysate (Fig. 3.22.E). The synthesis of the 
LPS-induced iNOS seems to be completely abolished by both dexamethasone and IL-10 
(~2% of proteins remains compared with LPS-treated cells). 
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Fig. 3.22. The synthesis of NO-synthase by resident and activated liver macrophages. Liver macrophages 
(primary culture) are incubated for 24 h in presence of LPS (500 ng/ml), rat IL-1ß (1 ng/ml) or/and with rat 
TNFa (10 ng/ml) or without stimuli. mRNA (A, B) and proteins (C) of NO-synthases are analyzed as described 
in “Materials and Methods”. A representative set of three independent experiments is shown. (B) The expression 
of enzyme in unstimulated cells corresponds 100, in LPS-, IL-1ß- and TNFa-treated cells is 3793±576, 220±81 
and 243±120, respectively (n=3); (C) The synthesis of enzyme in unstimulated cells corresponds 100, in LPS-, 
IL-1ß- and TNFa-treated cells is 12024±3488, 340±70 and 335±135, respectively (n=2). (D, E) Regulation of 
iNOS by dexamethasone and IL-10 in LPS-activated macrophages. Cells are pre-treated for with IL-10 (10 
ng/ml) and dexamethasone (Dex, 1 µM) for 1 h. Then fresh medium with LPS (+LPS; 500 ng/ml) or without (-
LPS) is added and macrophages are incubated for 24 h. mRNA (D) or proteins (E) are analyzed. A representative 
set of three independent experiments is shown. (D) The expression of iNOS in IL-10/LPS- and Dex/LPS- treated 
cells is 22±10 and 2±0, respectively (24 h, +LPS corresponds 100); (E) the synthesis of iNOS in IL-10/LPS- and 
Dex/LPS- treated cells is 2±1 and 2±2, respectively (24 h, +LPS corresponds 100).
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3.5. Interaction of nitric oxide and prostanoid pathways in Kupffer cells 
 
3.5.1. Effect of NO on prostanoid synthesis 
 
3.5.1.1. Effect of NO-donor on prostanoid synthesis 
 
The effect of exogenous nitric oxide on prostanoid synthesis is assessed with the NO-donor S-
Nitroso-N-acetylpenicillamine (SNAP), which delivers nitric oxide in aqueous buffers (t½ = 
10 h) (Fig. 3.23.A). It is found, that SNAP leads to the formation of NO in a concentration-
dependent way and to a release of PGE2 (Fig. 3.23.A).  
Simultaneously, SNAP induces in a concentration-dependent way the expression of cPLA2, 
COX-1 and mPGES-1 (Fig. 3.23.A). 
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Fig. 3.23. Effect of SNAP and endogenous NO on the PGE2 release and enzymes. Liver macrophages are 
incubated with SNAP (S-Nitroso-N-acetylpenicillamine; 1, 10 or 100 µM) or vehicle (C) for 24 h. (A) The 
amounts of nitric oxide and PGE2 in the medium are determined by Griess assay and specific ELISA, 
respectively (the values are corrected for NO and PGE2 formed in the absence of stimuli). Data shown are 
means of at least three independent experiments ± S.E. The release of PGE2 in SNAP(1 µM)/LPS-treated cells 
is equal to 81% ±5%, when the release of PGE2 in LPS-treated cells is 18.7±3.9 pmol/106 cells/24 h.
(B) Proteins are analyzed as described in “Materials and Methods”. A representative set of at least two 
independent experiments is shown. The synthesis of enzymes after tretament for 24 h with 10 µM and 100 µM
of SNAP are (24 h, no stimuli, corresponds 100): cPLA2 156±2 / 187±43; COX-2  129±27 / 170±26; mPGES-1 
251±61 / 282±87, respectively.
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Fig. 3.23. 
3.5.1.2. Blockade of endogenous nitric oxide secretion 
 
The downregulation of endogenous nitric oxide release by LPS-activated Kupffer cells is 
studied by two NOS inhibitors: L-NMMA (NG-Monomethyl-L-arginine monoacetate) which 
competitively inhibits three isoforms of NOS and by L-NIL (L-N6-(1-Iminoethyl) lysine) 
which acts as a selective inhibitor of iNOS. Kupffer cells, treated with LPS and inhibitors 
showed a strong reduction of NO release (Table 3.3.). The specific inhibition of iNOS by L-
NIL is more effective as the non-specific inhibition by L-NMMA.  
L-NIL and L-NMMA lead to a weak inhibition of PGE2-release. 
L-NIL and L-NMMA have no effect on the expression of cPLA2, COX-2 and mPGES-1 (Fig. 
3.24.).  
 
 
 
Table 3.3. The inhibition of NO and PGE2 release by L-NIL and L-NMMA. Liver macrophages   (primary 
culture)  are  pretreated  for  15 min with L-NMMA (NG-Monomethyl-L-arginine monoacetate, 10 µg/ml), L-
NIL (L-N6-(1-Iminoethyl) lysine; 10 µM) or solvent. Then fresh medium with/without LPS (500 ng/ml) is added 
and macrophages are incubated for the indicated times. The amounts of NO and PGE2 in cell media are 
determined by Griess assay or ELISA, respectively, as described in “Material and Methods”. Data shown are 
means ± S.E of at least three independent experiments. The release of NO and PGE2 in LPS-pretreated cells is 
95±15 nmol/106 cells and 23±4 pmol/106 cells, respectively. *P<0.01, *P <0.055.
L-NIL
L-NMMA
% of inhibition
PGE2
69 ± 4*
59 ± 8*
15 ± 7**
15 ± 5**
NO
Table 3.3. 
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Fig. 3.24. Effect of L-NMMA and L-NIL on the enzyme synthesis. Cells are kept as described in the Table 
3.3. Proteins are analyzed as described in “Material and Methods”. A representative set of three independent 
experiments is shown. The synthesis of enzymes in L-NMMA/LPS- and L-NIL/LPS-treated cells is (24 h, 
+LPS corresponds 100): cPLA2 81±4 / 99±5; COX-2 104±3 / 115±13; mPGES-1 108±8 / 132±9, respectively.
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Fig. 3.24. 
 
 
 
 
3.5.2. Effect of PGE2 on NO synthesis 
 
3.5.2.1. Effect of exogenously added PGE2 on nitric oxide synthesis 
 
PGE2 affects differently the NO synthesis in liver KC (Fig. 3.25., Fig. 3.26.):  
1) PGE2, added exogenously to the resident cells has no effect on NO release (data not 
shown); 
2) PGE2, added exogenously to LPS-treated KC inhibits the NO release to 60% (Fig. 
3.25.A). The exogenous PGE2 downregulates iNOS mRNA and proteins by more than 
90% (Fig. 3.26.); 
3) PGE2, added exogenously to cytokines-treated KC, increases NO release by 140% 
(IL-1β), 400% (TNFα) and about 400% (IL-1β/TNFα). 
 
 
 
III. Results                                                                80 
   
Fig. 3.25. Effect of PGE2 on the release of NO by LPS-(A) and cytokines-(B) activated KC. Liver 
macrophages are pre-incubated with PGE2 (1 µM) during 1 h. Thereafter fresh medium with LPS (500 ng/ml), 
rat IL-1ß (5 ng/ml) or/and rat TNFa (10 ng/ml) is added and macrophages are incubated for 24 h. The amounts 
of nitric oxide are determined by Griess assay as described in “Material and Methods”. Data shown are means ±
S.E. of at least three independent experiments.  (A) #P<0.05 vs. LPS. The release of nitric oxide in resting and 
PGE2-treated KC is 1.3±0.2 and 1.6±0.2 nmol/106 cells/24 h, respectively. (B) 100% corresponds the cytokines-
mediated NO release in absence of PGE2 (in nmol/106 cells/24 h): 10.1±1.4, 7.8±1.4 and 9.2±2.0 after 
incubation with IL-1ß, TNFa and IL-1ß+TNFa, respectively.*P<0.01 and **P<0.05 vs. cytokines.
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Fig. 3.26. Effect of exogenously added PGE2 on inducible NO synthase. Liver macrophages are pre-
incubated with PGE2 (1 µM) during 1 h. Thereafter fresh medium with/without LPS (500 ng/ml) is added and 
macrophages are incubated for 24 h. mRNA (A) or proteins (B) are analyzed as described in “Materials and 
Methods”. A representative set of three independent experiments is shown. The following data of densitometric 
analysis are obtained (24 h, +LPS corresponds 100): mRNA - 9±5, proteins - 4±2 after incubation with PGE2
and LPS for 24 h.
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Fig. 3.26. 
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3.5.2.2. Effect of cell-derived PGE2 on nitric oxide production 
 
Indomethacin is a member of the non-steroidal anti-inflammatory drug family, capable to 
inhibit both COX-1 and COX-2. PGE2 synthesis in LPS-activated liver macrophages is almost 
completely inhibited by indomethacin (Fig. 3.27.A).  
Indomethacin suppresses about 40% of NO release.  
It has no effect on the expression of iNOS, cPLA2, COX-2 and mPGES-1 (Fig. 3.27.B). 
 
 
 
Fig. 3.27. Effect of indomethacin on the release of both PGE2 and NO and on the synthesis of 
corresponding enzymes. Liver macrophages   (primary culture)  are  pretreated  for  1 h with indomethacin (1 
µM) or solvent. Then fresh medium with/without LPS (500 ng/ml) is added and macrophages are incubated for 
24 h. (A) The amounts of PGE2 and NO in the supernatants are determined by specific ELISA or by Griess 
assay, respectively, as described in “Material and Methods”. Data shown are means ± S.E of eight independent 
experiments. The release of PGE2 and NO LPS-treated cells is 20±1 pmol/106 cells and 74±15 nmol/106 cells. 
*P<0.001, **P <0.05 vs. LPS-treated macrophages. (B) Proteins are analyzed as described in “Materials and 
Methods”. A representative set of three independent experiments is shown. The synthesis of indicated enzymes 
in indomethacin/LPS-treated cells is (24 h, +LPS corresponds 100): iNOS 96±5; cPLA2 89±6; COX-2 106±11; 
mPGES-1 94±14.
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4. Discussion 
 
 
This study focuses on the prostanoid and nitric oxide production by rat liver macrophages, on 
the interaction of their synthesis pathways and on the regulation of their synthesis by pro- and 
ant-fibrogenic cytokines. 
 
 
4.1. Study of prostanoid synthesis 
 
Prostanoids play significant role in the organism and in the liver in particular. PGE2 release is  
strongly enhanced by pro-inflammatory stimuli (Dieter et al., 1995; Ambs et al., 1995; Dieter 
et al., 2002; Dieter et al., 2000) and plays an important role in the regulation of liver 
(patho)physiology (Dieter et al., 2001). Thromboxane A2 is a potent modulator, involved in 
pathophysiology and is released from Kupffer cells (Decker, 1990). 
 
The present study demonstrates that rat liver macrophages release an enhanced amount of 
PGE2 and TxA2 during the prolonged incubation with LPS.  
In recent studies there has been shown, that lipopolysacharide – a potent bacterial endotoxin 
from the outer membrane of gram-negative bacteria - provokes a strong inflammatory 
response by macrophages (Dieter et al., 1995), in particular by Kupffer cells (Ambs et al., 
1995; Thoren et al., 2000). In contrast to other stimuli (e.g. zymosan, phobol ester, Ca2+ 
ionophore) which lead to an immediate release of mediators in the cultivation medium (Ambs 
et al., 1995), the response of macrophages on LPS activation occurs often  after a lag phase of 
several hours.  
 
The release of TxA2 is fast and becomes considerable already after 2 h of incubation; 
thereafter the rate of synthesis declines. In opposite, PGE2 release shows a “lag-phase” and 
becomes measurable after 4 h of incubation. Thereafter, it displays an almost linear 
dependence on the time of incubation, increasing gradually during the next 20 h. 
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Dexamethasone downregulates the PGE2 and TxA2 release, like in human A549 cell line 
(Thoren et al., 2000), in rat peritoneal macrophages (Murakami et al., 2000) or in human 
rheumatoid synoviocytes (Stichtenoth et al., 2001).  
The distinction in the release kinetics of both TxA2 and PGE2, together with earlier findings 
(Dieter et al., 1989) suggest different regulatory mechanisms in their synthesis pathways. The 
synthesis of prostanoids goes through the three consecutive stages, including i) release of AA 
by cPLA2, ii) its successive conversion into PG G2/H2 by means of cyclooxygenase 
isoenzymes and iii) the subsequent synthesis of prostanoids from PG G2/H2 through the action 
of final prostanoid synthases. Each step of the prostanoid synthesis is an object for the 
regulation by pro- and anti-inflammatorFy agents. 
 
The regulation can occur on the enzymes activities as well as on transcription and translation 
level. Here is demonstrated that LPS induces a coordinate expression of cPLA2, COX-2 and 
mPGES-1, while COX-1, cPGES, mPGES-2 and TxAS remain unchanged. In detail: 
 
 
1) cPLA2: cPLA2 is expressed at low levels in resident KC. cPLA2 protein is localized 
predominantly in the membrane fraction. LPS induces also a phosphorylation of cPLA2. 
These studies confirm earlier findings (Ambs et al., 1995) that cPLA2 undergoes induction 
and posttranslational modification through phosphorylation when KC are exposed to LPS; 
 
2) Cyclooxygenases: COX-1 is expressed in resident KC. COX-1 does not undergo 
significant changes on both transcriptional and translational level by LPS. COX-2 is detected 
in resident KC at very low levels. LPS induces an enhanced mRNA expression with a 
maximum at 4 h. COX-2 protein is synthesized in a linear mode reaching a maximum after 24 
h of incubation. Both, mRNA encoding COX-2 and COX-2 protein are completely suppressed 
by dexamethasone. Both, COX-1 and COX–2 are localized mainly in the membrane fraction. 
 
3) Final prostaglandin synthases:  
- mPGES-1: is expressed at very low level in resident cells; LPS induces a high 
induction at mRNA and protein level; present in microsomal fraction;  
- mPGES-2: is expressed in resident cells; LPS induces a weak induction at mRNA 
and a prolonged induction at translation level; present in microsomal and partially 
in cytosolic fraction;  
IV. Discussion                                                               84 
   
- cPGES: is expressed in resident cells; LPS does not alter expression at mRNA and 
protein level; present in cytosolic fraction; 
- TxAS: like cPGES; present in microsomal and (partially) in cytosolic fraction. 
TxAS activity is not changed by LPS. 
 
PGE2 synthesis and release might be regulated by means of activation/suppression of each 
steps i) cPLA2, COX-2, mPGES-1 and mPGES-2 or by means of posttranslational 
modifications of cPGES (Tanioka et al., 2003; Kobayashi et al., 2004). It has been shown that 
the LPS-induced mPGES expression is regulated through a Toll-like receptor 4 
(TLR4)/MyD88-dependent pathway and depended upon the NF-IL6 transcription factor 
(Uematsu et al., 2002); stimuli-induced expression of the mouse and human mPGES has been 
found to require the inducible nuclear protein Egr-1 (Early Growth Response–1) (Naraba et 
al., 2002). 
 
Another aspect of regulation is the question how much each distinct enzyme contributes to 
PGE2 production.  These questions on the coupling between the different PGES and COX 
enzymes are widely discussed (Dieter et al., 2000; Lazarus et al., 2002a; Naraba et al., 1998; 
Tanioka et al., 2000; Murakami et al., 2000; Thoren et al., 2000; Stichtenoth et al., 2001).  A 
previous study using specific COX-1 and COX-2 inhibitors demonstrates that in Kupffer cells 
PGE2 is more effectively coupled to COX-1 (Dieter et al., 2000). Other studies have been 
recently performed with cotransfection of cPGES (Tanioka et al., 2000) and mPGES-1 
(Murakami et al., 2000) showing a coupling between COX-2 and mPGES-1, and COX-1 and 
cPGES. Also a colocalization of mPGES-1 and COX-2 in mice has been detected by Lazarus 
et al., 2002b. In contrast, another study demonstrates that mPGES-1 is coupled to COX-1 
only in an immediate activation of cPLA2, but in a delayed response mPGES-1 is coupled to 
COX-2 (Murakami et al., 2000). These studies suggest that the coupling process might 
depend on the tissue and/or the stimulus. 
 
Here, using specific COX-1 and COX-2 inhibitors it is shown that in general COX-1 is more 
involved in release of TxA2, whereas COX-2 mediates the release of PGE2  (Fig. 4.1.). 
However, the participation of the COX isoenzymes is also dependent on the time of the 
release: in TxA2 release COX-2 becomes more significant at earlier time point, in PGE2 
release COX-1 becomes more significant at later time point.    
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The coupling to the final prostanoid synthases can only be hypothesized at present: in the 
early release, the COX isoenzymes couple to the pre-existing cPGES, mPGES-2 and TxAS. 
The level of the induced mPGES-1 at later time points have to be further investigated.  
 
 
 
 
 
 
Fig. 4.1. Tentative scheme for LPS-induced release of PGE2 and TxA2 in liver 
macrophages.
 
Fig. 4.1. 
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4.2. Effect of cytokines on resident and LPS-activated cells 
 
4.2.1. Pro-fibrogenic cytokines activate the synthesis of prostanoids 
 
Numerous studies report that under inflammatory conditions KC release cytokines of the 
acute phase response, such as IL-1β, TNFα and IL-6 (Fig. 4.2.) (Decker, 1990; Treffkorn et 
al., 2004; Karck et al., 1988; Oguro et al., 2002; Nunez et al., 2005). Other liver cells are also 
capable to release pro-fibrogenic cytokines (Malik et al., 2002; Olinga et al., 2001).  
The present study shows that both IL-1β and TNFα induce the synthesis of PGE2 and TxA2. 
The cytokines exert a synergistic effect on PGE2, but not on a TxA2 release. The cytokine-
mediated regulation of prostanoid synthesis occurs on the level of mRNA and protein of 
cPLA2, COX-2 and mPGES-1.  
 
 
 
 
Fig. 4.2. Tentative schema of cytokine and prostanoid interaction
Fig. 4.2. 
 
 
In contrast, IL-6 does not have a effect on the release of prostanoids. IL-6 has been designated  
to be a proliferative factor for rat HSC and hepatocytes (Malik et al., 2002). 
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4.2.2. Anti-fibrogenic cytokines  
 
IL-10 is widely produced by liver cells in vivo and in vitro, protecting the liver against injury. 
For instance, IL-10 has been reported to suppress the hepatic injury in mice (Ju et al., 2002; 
Kahlke et al., 2002; Thompson et al., 1998), to modulate  TNFa action  in vitro on rat hepatic 
macrophages (Tran-Thi et al., 1995) and human choriodecidua (Sato et al., 2003). A 
regulatory effect of IL-10 on prostanoid production has been previously described in an 
endotoxine-mediated mice model (Berg et al., 2001), in human monocytes (Niiro et al., 1995) 
and neutrophils (Nagano et al., 2002). 
Here it is shown that LPS-induced release of PGE2 and TxA2 is suppressed by IL-10 on the 
level of mRNA and protein of cPLA2, COX-2 and mPGES-1. Thus, IL-10 abrogates not only 
the LPS-induced increase of cPLA2 and COX-2 expression (Fernandez-Morata et al., 2000; 
Nagano et al., 2002; Berg et al., 2001; Niiro et al., 1995). Our result is consistent with the 
recent studies demonstrating a hepato-protective properties of IL-10 (Olinga et al., 2001; 
Nelson et al., 2003; Pinzani et al., 2001; Kojima et al., 2003).  
 
4.3. Production of nitric oxide by rat liver macrophages 
 
 
The role of nitric oxide in the liver is dualistic, but it is clear that it regulates a number of 
(patho)physiological processes in the liver. For instance, NO has been shown to be harmful or 
protective for hepatocytes (Kawada N., 1999), to affect the transcription of genes that 
modulate post-injury proliferation or cell death (Horton et al., 1994), to nitrosylate cellular 
enzymes (Liu et al., 2002) and to inhibit mitochondrial respiratory chain enzymes and 
glyconeogenesis (Horton et al., 1994). Furthermore, NO has been shown to play an essential 
role in the initiation of the inflammatory response in the liver (Liu et al., 2002) and to 
modulate the hepatocyte’s response to injury. Nitric oxide may also prevent the necrotic cell 
death following endotoxemia-induced liver damage (Ou et al., 1997). In hepatocyte cultures 
nitric oxide has been shown to inhibit total protein synthesis and bile canalicular contraction 
(Gaillard et al., 1991) and to prevent apoptosis (Harbrecht et al., 1995).  
 
The synthesis of NO in rat Kupffer cells has been demonstrated earlier (Decker, 1990; Stadler 
et al., 1993; Gaillard et al., 1991).  
IV. Discussion                                                               88 
   
Here it is shown that treatment of rat liver macrophages with LPS leads to the expression of 
iNOS and to the release of NO. 
Furthermore, we provide evidence that IL-1β and TNFα induce a small release of NO and 
exert a small induction of iNOS mRNA and protein expression.  
In contrast,  IL-10 strongly abrogates the LPS-mediated NO release and mRNA and protein 
expression of iNOS in rat liver macrophages.  
 
4.4. Interaction of prostanoids and nitric oxide biosynthesis pathways 
 
To examine the effect of exogenous nitric oxide on the PGE2 release and its synthesis 
pathways, NO-donor SNAP has been used in this study. It is shown that endogenous NO 
induces synthesis of PGE2, expression of cPLA2, COX-2 and mPGES-1. 
 
Furthermore, the effect of a suppression of endogenous nitric oxide release by NOS inhibitors 
(L-NMMA, L-NIL) is examined. Both inhibitors lead to a small suppression of PGE2 release, 
but do not affect the enzyme expression.  
 
Fig. 4.3. Interaction between prostanoid and NO release system in rat Kupffer cells.
(Nitric oxide synthesis has been demonstrated in J Appl Toxicol. 2000;20(3):189-95.)
LPS, Cytokines
Fig. 4.3. 
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In literature, opposite effects of PGE2 and NO release have been described (Harbrecht et al., 
1995; Gaillard et al., 1991). 
 
Here it is shown that: 
• PGE2 has no effect on NO release in resident cells; 
• PGE2 inhibits NO release and iNOS mRNA and protein in LPS-simulated cells; 
• PGE2 induces a small (IL-1β) and a strong (TNFα) increase in NO release;  
Inhibition of PGE2 release by indomethacin leads to an inhibition of the LPS-mediated nitric 
oxide production; but does not affect the expression of iNOS. 
 
These data are interpreted (Fig. 4.3.) as follows: 
• Nitric oxide is a potent regulator of PGE2 release; 
• PGE2 is a potent regulator of NO release; 
Our data are consistent with previous studies in other animal models (Watkins et al., 1997; 
Fermor et al., 2002; Gallo et al., 2002; Perkins et al., 1999).  
 
 
4.5. Prostanoids are important regulators of the liver (patho)physiology 
 
 
Prostanoids play an important regulatory role in the liver in normal and inflammatory 
conditions (Dieter et al., 1999; Dieter et al., 2001). They exert an effect on the production of 
other macrophage-derived mediators, like cytokines and NO and they regulate prostanoid 
release in an autocrine way. 
In detail:   
• LPS induce a strong release of TxA2; 
• TNFα upregulates TxA2 release whereas IL-1β shows only a small response; 
• LPS-induced expression of cPLA2, COX-2 and mPGES-1 is strongly inhibited by 
PGE2; 
• TNFα-induced expression of enzymes is upregulated by PGE2. 
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Fig. 4.4. Schematic presentation of prostanoids, cytokines and nitric oxide network in 
liver macrophages during fibrogenesis
 
Fig. 4.4. 
 
These data confirm preliminarily studies on the action of PGE2 in liver macrophages (Fig. 
4.4.).  
PGE2 exerts action as an anti-fibrogenic mediator by modulation of: 
- pro-fibrogenic mediators as TNFα (Shinomiya et al., 2001), IL-1β (Goss et al., 
1993), TxA2; 
- anti-fibrogenic mediators as IL-10 (Goss et al., 1993) and NO; 
and by that inhibits the process of liver fibrogenesis. 
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SUMMARY 
 
Resident liver macrophages (Kupffer cells) play an important role in liver injury and liver 
fibrogenesis. They are the main producers of inflammatory mediators within the liver and are 
capable to release pro-fibrogenic mediators like IL-1β, TNFα, IL-6, TxA2 and anti-fibrogenic 
mediators like PGE2, NO and IL-10. 
Furthermore, liver macrophages are the high-capacity source of prostanoids (PGE2, TxA2) in 
the liver. Prostanoid synthesis consists of several steps including arachidonic acid release by 
phospholipase (cPLA2), the conversion of AA in prostaglandin G2/H2 by cyclooxygenases 
(COX-1 and COX-2) and the synthesis of prostanoids by different final prostanoid synthases.  
LPS and dexamethasone have opposite effects on the release of PGE2 and TxA2, and on the 
expression of enzymes involved in the synthesis of these two mediators; LPS upregulates the 
release of PGE2 and TxA2 and the expression of COX-2 and mPGES-1; dexamethasone 
suppresses the induction.  
COX-1 and COX-2 contribute differently to the LPS-induced release of PGE2 and TxA2 in a 
time-dependent way. 
LPS also induces an expression of iNOS and a release of NO, dexamethasone suppresses the 
upregulation. 
The cytokines, IL-1β and TNFα, induce a release of PGE2, TxA2 and NO and an expression of 
cPLA2, COX-2, mPGES-1 and iNOS. IL-6 has no effect. IL-10 suppresses the LPS-mediated 
release of PGE2 and NO and the expression of correspondent enzymes.  
Endogenous NO leads to an enhanced release of PGE2 and expression of cPLA2, COX-2 and 
mPGES-1. Inhibition of NO release leads to a decreased release of PGE2. Inhibition of PGE2 
release leads to a decreased release of NO.  
Exogenously added PGE2 reduces the LPS-induced release of NO and TxA2 but augments the 
TNFα- and IL-1β-induced release of NO and TxA2.     
These results demonstrate a crosstalk between the prostanoids, cytokines and NO in Kupffer 
cells which might be very important in the development of liver fibrosis. 
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